



IDRS



AUSTRALIAN DRUG TRENDS 2024

Key Findings from the National Illicit Drug
Reporting System (IDRS) Interviews



AUSTRALIAN DRUG TRENDS 2024: KEY FINDINGS FROM THE NATIONAL ILLICIT DRUG REPORTING SYSTEM (IDRS) INTERVIEWS

Rachel Sutherland¹, Antonia Karlsson¹, Julia Uporova¹, Udesha Chandrasena¹, Haniene Tayeb¹, Olivia Price¹, Raimondo Bruno^{1,2}, Paul Dietze^{1,3,4}, Simon Lenton^{1,3,4}, Caroline Salom^{1,5}, Sophie Radke², Dylan Vella-Horne³, Sophie Haywood⁴, Catherine Daly⁵, Natalie Thomas⁵, Louisa Degenhardt¹, Michael Farrell¹ & Amy Peacock^{1,2}

¹ National Drug and Alcohol Research Centre, University of New South Wales Sydney

² School of Psychology, University of Tasmania

³ Disease Elimination Program, Burnet Institute

⁴ National Drug Research Institute and enAble Institute, Curtin University

⁵ Institute for Social Science Research, The University of Queensland



ISSN 2981-9326 ©NDARC 2024

This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia.

Suggested citation: Sutherland R, Karlsson A, Uporova J, Chandrasena U, Tayeb H, Price O, Bruno R, Dietze P, Lenton S, Salom C, Radke S, Vella-Horne D, Haywood S, Daly C, Thomas N, Degenhardt L, Farrell M, & Peacock A. Australian Drug Trends 2024: Key Findings from the National Illicit Drug Reporting System (IDRS) Interviews. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney; 2024. Available from: <https://doi.org/10.26190/unsworks/30464>

Please note that as with all statistical reports there is the potential for minor revisions to data in this report over its life. Please refer to the online version at [Drug Trends](#).

This report was prepared by the National Drug and Alcohol Research Centre, UNSW Sydney. Please contact the Drug Trends team with any queries regarding this publication: drugtrends@unsw.edu.au

Table of Contents

BACKGROUND AND METHODS	15
SAMPLE CHARACTERISTICS	19
HEROIN	26
METHAMPHETAMINE	34
COCAINE	50
CANNABIS AND/OR CANNABINOID-RELATED PRODUCTS	58
PHARMACEUTICAL OPIOIDS	70
OTHER DRUGS	85
DRUG-RELATED HARMS AND OTHER BEHAVIOURS	95

List of Tables

TABLE 1: GUIDE TO TABLE/FIGURE NOTES	18
TABLE 2: DEMOGRAPHIC CHARACTERISTICS OF THE SAMPLE, NATIONALLY, 2023-2024, AND BY CAPITAL CITY, 2024.....	21
TABLE 3: PAST SIX MONTH USE OF HEROIN, BY CAPITAL CITY, 2000–2024.....	29
TABLE 4: PAST SIX MONTH USE OF ANY METHAMPHETAMINE, BY CAPITAL CITY, 2000–2024.....	38
TABLE 5: PAST SIX MONTH USE OF POWDER METHAMPHETAMINE, BY CAPITAL CITY, 2000-2024	41
TABLE 6: PAST SIX MONTH USE OF BASE METHAMPHETAMINE, BY CAPITAL CITY, 2001-2024.....	42
TABLE 7: PAST SIX MONTH USE OF CRYSTAL METHAMPHETAMINE, BY CAPITAL CITY, 2000-2024.....	43
TABLE 8: PAST SIX MONTH USE OF COCAINE, BY CAPITAL CITY, 2000-2024	53
TABLE 9: PAST SIX MONTH NON-PRESCRIBED USE OF CANNABIS AND CANNABINOID-RELATED PRODUCTS, BY CAPITAL CITY, 2000-2024	62
TABLE 10: PAST SIX MONTH NON-PRESCRIBED USE OF METHADONE, BY CAPITAL CITY, 2003-2024.....	73
TABLE 11: PAST SIX MONTH NON-PRESCRIBED USE OF BUPRENORPHINE TABLET, BY CAPITAL CITY, 2003-2024	75
TABLE 12: PAST SIX MONTH NON-PRESCRIBED USE OF BUPRENORPHINE-NALOXONE (ANY FORM), BY CAPITAL CITY, 2006-2024	77
TABLE 13: PAST SIX MONTH NON-PRESCRIBED USE OF MORPHINE, BY CAPITAL CITY, 2006-2024.....	79
TABLE 14: PAST SIX MONTH NON-PRESCRIBED USE OF OXYCODONE, BY CAPITAL CITY, 2005-2024.....	81
TABLE 15: PAST SIX MONTH NON-PRESCRIBED USE OF FENTANYL, BY CAPITAL CITY, 2018-2024.....	83
TABLE 16: PAST SIX MONTH USE OF OTHER OPIOIDS, NATIONALLY, 2019-2024.....	84
TABLE 17: PAST SIX MONTH USE OF NEW PSYCHOACTIVE SUBSTANCES, NATIONALLY, 2013-2024	87
TABLE 18: PAST 12-MONTH NON-FATAL OVERDOSE BY DRUG TYPE, NATIONALLY, 2022-2024, AND BY CAPITAL CITY, 2024	102
TABLE 19: AUDIT-C TOTAL SCORES AND PER CENT OF PARTICIPANTS SCORING ABOVE RECOMMENDED LEVELS, NATIONALLY, 2010-2024.....	103
TABLE 20: LIFETIME AWARENESS OF NALOXONE, AND PAST YEAR ACCESS AND EDUCATION IN NALOXONE ADMINISTRATION, BY CAPITAL CITY, 2024	106
TABLE 21: INJECTING EQUIPMENT ACCESS IN PAST MONTH, NATIONALLY, 2023-2024 AND BY CAPITAL CITY, 2024.....	108
TABLE 22: INJECTING BEHAVIOURS IN THE PAST MONTH, AND LOCATION OF LAST INJECTION USE, NATIONALLY, 2023-2024, AND BY CAPITAL CITY, 2024.....	110
TABLE 23: INJECTION-RELATED ISSUES IN THE PAST MONTH, NATIONALLY, 2023-2024, AND BY CAPITAL CITY, 2024.....	111
TABLE 24: ANY CURRENT DRUG TREATMENT, NATIONALLY, 2022-2024, AND BY CAPITAL CITY, 2024	112
TABLE 25: TOTAL OPIOID AND METHAMPHETAMINE SDS SCORES AND PER CENT OF PARTICIPANTS SCORING ABOVE CUT-OFF SCORES INDICATIVE OF DEPENDENCE, AMONG THOSE WHO REPORTED PAST SIX MONTH USE, NATIONALLY, 2017-2024	114
TABLE 26: HCV AND HIV TESTING AND TREATMENT, NATIONALLY, 2018-2024.....	115
TABLE 27: SEXUAL HEALTH BEHAVIOURS, NATIONALLY, 2022-2024.....	116
TABLE 28: TYPES OF HEALTH SERVICES ACCESSED FOR ALCOHOL AND OTHER DRUG REASONS AND FOR ANY REASON IN THE PAST SIX MONTHS, NATIONALLY, 2022-2024	120
TABLE 29: PURCHASING APPROACHES IN THE PAST 12 MONTHS, NATIONALLY, 2023-2024.....	127

List of Figures

FIGURE 1: DRUG OF CHOICE, NATIONALLY, 2000-2024	23
FIGURE 2: DRUG INJECTED MOST OFTEN IN THE PAST MONTH, NATIONALLY, 2000-2024	24
FIGURE 3: WEEKLY OR MORE FREQUENT SUBSTANCE USE IN THE PAST SIX MONTHS, NATIONALLY, 2000-2024	25
FIGURE 4: PAST SIX MONTH USE AND FREQUENCY OF USE OF HEROIN, NATIONALLY, 2000-2024	28
FIGURE 5: MEDIAN PRICE OF HEROIN PER CAP, POINT AND GRAM, NATIONALLY, 2000-2024	31
FIGURE 6: CURRENT PERCEIVED PURITY OF HEROIN, NATIONALLY, 2000-2024	32
FIGURE 7: CURRENT PERCEIVED AVAILABILITY OF HEROIN, NATIONALLY, 2000-2024	33
FIGURE 8: PAST SIX MONTH USE OF ANY METHAMPHETAMINE AND OF METHAMPHETAMINE POWDER, BASE, AND CRYSTAL, NATIONALLY, 2000-2024	36
FIGURE 9: FREQUENCY OF USE OF ANY METHAMPHETAMINE AND OF METHAMPHETAMINE POWDER, BASE, AND CRYSTAL, NATIONALLY, 2000-2024	37
FIGURE 10: MEDIAN PRICE OF POWDER METHAMPHETAMINE PER POINT AND GRAM, NATIONALLY, 2002-2024	45
FIGURE 11: MEDIAN PRICE OF METHAMPHETAMINE CRYSTAL PER POINT AND GRAM, NATIONALLY, 2001-2024	45
FIGURE 12: CURRENT PERCEIVED PURITY OF POWDER METHAMPHETAMINE, NATIONALLY, 2002-2024	46
FIGURE 13: CURRENT PERCEIVED PURITY OF CRYSTAL METHAMPHETAMINE, NATIONALLY, 2002-2024	47
FIGURE 14: CURRENT PERCEIVED AVAILABILITY OF POWDER METHAMPHETAMINE, NATIONALLY, 2002-2024	48
FIGURE 15: CURRENT PERCEIVED AVAILABILITY OF CRYSTAL METHAMPHETAMINE, NATIONALLY, 2002-2024	49
FIGURE 16: PAST SIX MONTH USE AND FREQUENCY OF USE OF COCAINE, NATIONALLY, 2000-2024	52
FIGURE 17: MEDIAN PRICE OF COCAINE PER CAP/POINT AND GRAM, NATIONALLY, 2000-2024	55
FIGURE 18: CURRENT PERCEIVED PURITY OF COCAINE, NATIONALLY, 2000-2024	56
FIGURE 19: CURRENT PERCEIVED AVAILABILITY OF COCAINE, NATIONALLY, 2000-2024	57
FIGURE 20: PAST SIX MONTH USE AND FREQUENCY OF USE OF NON-PRESCRIBED CANNABIS AND CANNABINOID-RELATED PRODUCTS, NATIONALLY, 2000-2024	61
FIGURE 21: PAST SIX MONTH USE OF DIFFERENT FORMS OF NON-PRESCRIBED CANNABIS AND/OR CANNABINOID-RELATED PRODUCTS, AMONG THOSE WHO REPORTED RECENT NON-PRESCRIBED USE, NATIONALLY, 2018-2024	63
FIGURE 22: MEDIAN PRICE OF NON-PRESCRIBED HYDROPONIC (A) AND BUSH (B) CANNABIS PER OUNCE AND GRAM, NATIONALLY, 2003-2024	65
FIGURE 23: CURRENT PERCEIVED POTENCY OF NON-PRESCRIBED HYDROPONIC (A) AND BUSH (B) CANNABIS, NATIONALLY, 2004-2024	66
FIGURE 24: CURRENT PERCEIVED AVAILABILITY OF NON-PRESCRIBED HYDROPONIC (A) AND BUSH (B) CANNABIS, NATIONALLY, 2004-2024	68
FIGURE 25: PAST SIX MONTH USE (PRESCRIBED AND NON-PRESCRIBED) AND FREQUENCY OF USE OF NON-PRESCRIBED METHADONE, NATIONALLY, 2000-2024	72
FIGURE 26: PAST SIX MONTH USE (PRESCRIBED AND NON-PRESCRIBED) AND FREQUENCY OF USE OF NON-PRESCRIBED BUPRENORPHINE TABLET, NATIONALLY, 2002-2024	74
FIGURE 27: PAST SIX MONTH USE (PRESCRIBED AND NON-PRESCRIBED) AND FREQUENCY OF USE OF NON-PRESCRIBED BUPRENORPHINE-NALOXONE, NATIONALLY, 2006-2024	76

FIGURE 28: PAST SIX MONTH USE (PRESCRIBED AND NON-PRESCRIBED) AND FREQUENCY OF USE OF NON-PRESCRIBED MORPHINE, NATIONALLY, 2001-2024 78

FIGURE 29: PAST SIX MONTH USE (PRESCRIBED AND NON-PRESCRIBED) AND FREQUENCY OF USE OF NON-PRESCRIBED OXYCODONE, NATIONALLY, 2005-2024 80

FIGURE 30: PAST SIX MONTH USE (PRESCRIBED AND NON-PRESCRIBED) AND FREQUENCY OF USE OF NON-PRESCRIBED FENTANYL, NATIONALLY, 2013-2024 82

FIGURE 31: PAST SIX MONTH USE OF NON-PRESCRIBED PHARMACEUTICAL DRUGS, NATIONALLY, 2006-2024 90

FIGURE 32: PAST SIX MONTH USE OF LICIT AND OTHER DRUGS, NATIONALLY, 2000-2024 94

FIGURE 33: USE OF OPIOIDS, STIMULANTS, BENZODIAZEPINES AND CANNABIS ON THE DAY PRECEDING INTERVIEW AND MOST COMMON DRUG PATTERN PROFILES, NATIONALLY, 2024 96

FIGURE 34: PAST SIX MONTH USE OF DRUGS FOR 48 HOURS OR MORE CONTINUOUSLY WITHOUT SLEEP ('BINGE'), NATIONALLY, 2018-2024 98

FIGURE 35: PAST 12-MONTH ANY NON-FATAL OVERDOSE, NATIONALLY, 2000-2024 101

FIGURE 36: LIFETIME AWARENESS OF NALOXONE AND NALOXONE TAKE-HOME PROGRAMS, NATIONALLY, 2013-2024 105

FIGURE 37: PAST 12 MONTH EDUCATION IN NALOXONE ADMINISTRATION, AND OBTAINED NALOXONE, NATIONALLY, 2020-2024 105

FIGURE 38: BORROWING AND LENDING OF NEEDLES AND SHARING OF INJECTING EQUIPMENT IN THE PAST MONTH, NATIONALLY, 2000-2024 109

FIGURE 39: TREATMENT SATISFACTION AMONGST THOSE WHO REPORTED CURRENT TREATMENT, NATIONALLY, 2019-2024 113

FIGURE 40: SELF-REPORTED MENTAL HEALTH PROBLEMS AND TREATMENT SEEKING IN THE PAST SIX MONTHS, NATIONALLY, 2004-2024 117

FIGURE 41: K10 PSYCHOLOGICAL DISTRESS SCORES, NATIONALLY, 2007-2024 AND AMONG THE GENERAL POPULATION 2022-23 118

FIGURE 42: HEALTH SERVICE ACCESS FOR ALCOHOL AND OTHER DRUG REASONS, AND FOR ANY REASON IN THE PAST SIX MONTHS, NATIONALLY, 2018-2024 119

FIGURE 43: SELF-REPORTED TESTING, AND DRIVING OVER THE (PERCEIVED) LEGAL LIMIT FOR ALCOHOL OR WITHIN THREE HOURS FOLLOWING ILLICIT DRUG USE, AMONG THOSE WHO HAD DRIVEN IN THE LAST SIX MONTHS, NATIONALLY, 2007-2024 121

FIGURE 44: LIFETIME AND PAST YEAR ENGAGEMENT IN DRUG CHECKING, NATIONALLY, 2019-2024 122

FIGURE 45: SELF-REPORTED CRIMINAL ACTIVITY IN THE PAST MONTH, NATIONALLY, 2000-2024 124

FIGURE 46: VICTIM OF CRIME INVOLVING VIOLENCE IN THE PAST MONTH, NATIONALLY, 2019-2024 125

FIGURE 47: LIFETIME INCARCERATION, AND PAST 12 MONTH ARREST AND DRUG-RELATED ENCOUNTERS WITH POLICE THAT DID NOT RESULT IN ARREST, NATIONALLY, 2003-2024 126

Acknowledgements

Funding

In 2024, the Illicit Drug Reporting System (IDRS), falling within the Drug Trends program of work, was supported by funding from the Australian Government Department of Health and Aged Care under the Drug and Alcohol Program.

Research Team

The National Drug and Alcohol Research Centre (NDARC), UNSW Sydney, coordinated the IDRS. The following researchers and research institutions contributed to the IDRS in 2024:

- Dr Rachel Sutherland, Antonia Karlsson, Julia Uporova, Udesha Chandrasena, Olivia Price, Haniene Tayeb, Professor Louisa Degenhardt, Professor Michael Farrell and Associate Professor Amy Peacock, National Drug and Alcohol Research Centre, University of New South Wales Sydney, New South Wales;
- Dylan Vella-Horne and Professor Paul Dietze, Burnet, Victoria;
- Sophie Radke and Associate Professor Raimondo Bruno, School of Psychology, University of Tasmania, Tasmania;
- Sophie Haywood and Professor Simon Lenton, National Drug Research Institute and EnAble Institute, Curtin University, Western Australia; and
- Catherine Daly, Dr Natalie Thomas, Dr Jennifer Juckel, Lawrence Rivera and Associate Professor Caroline Salom, Institute for Social Science Research, The University of Queensland, Queensland.

We would like to thank past and present members of the research team.

Participants

We would like to thank all the participants who were interviewed for the IDRS in the present and in previous years.

Contributors

We thank all the individuals who contributed to questionnaire development and assisted with the collection and input of data at a jurisdictional and national level. We would like to thank the members of the Drug Trends Advisory Committee, as well as the Australian Injecting & Illicit Drug Users League (AIVL), for their contribution to the IDRS.

We acknowledge the traditional custodians of the land on which the work for this report was undertaken. We pay respect to Elders past, present, and emerging.

Abbreviations

ACT	Australian Capital Territory
Ade	Adelaide
AIVL	Australian Injecting & Illicit Drug Users League
Alpha PVP	α -Pyrrolidinopentiophenone
AOD	Alcohol and Other Drugs
AUDIT-C	Alcohol Use Disorders Identification Test-Concise
Bri/GC	Brisbane/Gold Coast
Can	Canberra
CBD	Cannabidiol
COVID-19	Coronavirus Disease 2019
CPR	Cardiopulmonary resuscitation
Dar	Darwin
DSM	Diagnostic and Statistical Manual of Mental Disorders
DMT	Dimethyltryptamine
EDRS	Ecstasy and Related Drugs Reporting System
GHB/GBL/1,4-BD	Gamma-hydroxybutyrate/Gamma-butyrolactone/1,4-Butanediol
GP	General Practitioner
HCV	Hepatitis C Virus
HIV	Human immunodeficiency virus
Hob	Hobart
IDRS	Illicit Drug Reporting System
IQR	Interquartile Range
K10	Kessler Psychological Distress Scale
LSD	<i>d</i> -lysergic acid
MDA	3,4-methylenedioxyamphetamine
MDPV	Methylenedioxypropylone
Melb	Melbourne
N (or n)	Number of Participants
NDARC	National Drug and Alcohol Research Centre
NHS	National Health Survey
NPS	New Psychoactive Substances
NSP	Needle and Syringe Program
NSW	New South Wales
NT	Northern Territory
OTC	Over-the-Counter
PBS	Pharmaceutical Benefits Scheme
PCR	Polymerase Chain Reaction

Per	Perth
PTSD	Post-traumatic stress disorder
QLD	Queensland
RNA	Ribonucleic Acid
SA	South Australia
SD	Standard Deviation
SDS	Severity of Dependence Scale
STI	Sexually Transmitted Infection
Syd	Sydney
TAS	Tasmania
TGA	Therapeutic Goods Administration
THC	Tetrahydrocannabinol
UNSW	University of New South Wales
VIC	Victoria
WA	Western Australia
WHO	World Health Organization

Executive Summary

The IDRS comprises a sentinel sample of people who regularly inject illicit drugs, recruited via advertisements in needle syringe programs and other harm reduction services, as well as via peer referral, across each capital city of Australia. The results are not representative of all people who inject drugs, nor of use in the general population. **Data were collected in 2024 from June-July. Since 2020, interviews were delivered face-to-face as well as via telephone, to reduce risk of COVID-19 transmission; all interviews prior to 2020 were conducted face-to-face. This methodological change should be factored into all comparisons of data from the 2020-2024 samples relative to previous years.**

Sample Characteristics

The 2024 IDRS sample (N=884) was mostly similar to the sample in 2023 and in previous years. Participants predominantly identified as male (69%) with a median age of 47 years, both stable from 2023. In 2024, most participants reported being unemployed at the time of the interview (89%; 86% in 2023), although the median weekly income significantly increased (\$424; \$400 in 2023; $p=0.006$). Drug of choice remained stable, with 42% nominating methamphetamine (45% in 2023) and 39% nominating heroin (41% in 2023) as their drug of choice. Most participants continued to nominate methamphetamine as the drug injected most often in the past month (59%; 56% in 2023).

Heroin

In 2024, 51% of the sample reported recent heroin use, stable relative to 2023 (56%). Median frequency of use also remained stable

at a median of 90 days (i.e., every second day) in the past six months (90 days in 2023). Among participants who had recently used heroin, 53% reported using white/off-white powder (59% in 2023; $p=0.015$). Price, perceived purity and perceived availability remained stable, with 39% reporting 'medium' purity (35% in 2023) and 91% reporting 'easy' or 'very easy' obtainment (91% in 2023).

Methamphetamine

Recent use of any methamphetamine has been gradually increasing since 2010, although has been relatively stable from 2021 onwards. In 2024, 82% reported recent use, stable from 2023 (81%). Crystal continued to be the most common form of methamphetamine used by participants (81%; 80% in 2023). Fewer participants reported consuming methamphetamine powder (8%; 10% in 2023) and base (5%; 5% in 2023). Among those who reported recent use, participants reported using methamphetamine crystal on average three times per week in the six months preceding the interview (72 median days; 72 days in 2023). The reported median price for one point of powder and crystal remained stable at \$50, respectively. Perceived purity for powder and crystal remained stable, albeit mixed. Perceived availability also remained stable, with 74% reporting 'easy' or 'very easy' obtainment of powder, and 95% reporting 'easy' or 'very easy' obtainment of crystal.

Cocaine

Recent use of cocaine and frequency of use has generally decreased amongst the sample since the commencement of monitoring (peak of 35% in 2001), although remained stable in 2024 relative to 2023. In 2024, 17% of participants

reported recent use on a median of 2 days. The median price for one gram of cocaine remained stable at \$300 (\$350 in 2023). Perceived purity and availability of cocaine also remained stable, with 50% of participants reporting 'high' purity (36% in 2023), and 67% reporting 'easy' or 'very easy' obtainment (68% in 2023).

Cannabis and/or Cannabinoid-Related Products

At least two thirds of the IDRS sample have reported recent use of non-prescribed cannabis and/or cannabinoid-related products since monitoring commenced. In 2024, 69% reported recent non-prescribed use (69% in 2023). Frequency of non-prescribed cannabis use remained stable at a median of 180 days (180 days in 2023), with 55% of those who had recently used cannabis reporting daily use (51% in 2023). There were no significant changes in relation to the perceived purity or availability of bush and hydroponic cannabis in 2024, relative to 2023. However, a significant decrease was observed for the price of one ounce of bush (\$180; \$250 in 2023; $p=0.039$).

Pharmaceutical Opioids

Non-prescribed use of all forms of pharmaceutical opioids has either remained stable or declined since monitoring of each opioid first commenced. In 2024, non-prescribed use of all pharmaceutical opioids remained stable relative to 2023, with morphine and oxycodone the most commonly used non-prescribed pharmaceutical opioids (10%, respectively). However, significant increases were observed in frequency of use for non-prescribed methadone syrup (12 days; 4 days in 2023; $p=0.041$) and non-prescribed buprenorphine-suboxone (7 days; 5 days in 2023; $p=0.008$).

Other Drugs

Use of any NPS has fluctuated between 5% and 12% since monitoring commenced in 2013, with 5% reporting recent use in 2024 (7% in 2023). Benzodiazepines remained the most common non-prescribed pharmaceutical drug reported by participants in 2024 (25%; 28% in 2023), followed by pregabalin (13%; 16% in 2023). Significant decreases were observed in participants' recent use of alcohol (51%; 57% in 2023; $p=0.020$) and non-prescribed e-cigarettes (27%; 34% in 2023; $p=0.005$), though frequency of use for both substances remained stable. Recent use of tobacco remained high yet stable (87%; 88% in 2023), with 53% reporting illicit tobacco use: both were used on a median of 180 days. Use of all other monitored drugs remained stable.

Drug-Related Harms and Other Behaviours

Polysubstance use and bingeing

In 2024, 63% of the sample reported using two or more drugs (excluding tobacco and e-cigarettes) on the day preceding interview.

Three fifths (61%) of the national IDRS sample had binged on one or more drugs for 48 hours or more in the six months preceding interview.

Injecting behaviours and equipment access

In 2024, 5% of participants reported receptive sharing of a needle or syringe (5% in 2023) and 9% reported distributive sharing in the past month (7% in 2023). One third (35%) reported re-using their own needles in the past month, stable relative to 2023 (33%), and 15% reported sharing other equipment, a significant decrease relative to 2023 (21%; $p=0.002$).

Twenty-nine per cent reported having an injection-related problem in the past month (26% in 2023), most commonly any infection/abscess (13%; 10% in 2023) and any nerve damage (12%; 10% in 2023).

Overdose, naloxone and drug checking

In 2024, one fifth (21%) of the sample reported any past 12-month non-fatal overdose, stable relative to 2023 (18%), most commonly from heroin (11%; 9% in 2023).

Awareness of take-home naloxone remained stable in 2024 (80%; 80% in 2023), as did past year access (46%; 44% in 2023).

In 2024, 11% of participants reported that they or someone else had tested the contents and/or purity of their illicit drugs in Australia in the past year (9% in 2023).

Dependence, drug treatment and HCV

In 2024, 36% of male participants obtained an AUDIT-C score of ≥ 4 , and 35% of female participants obtained a score of ≥ 3 , indicative of hazardous alcohol use.

Half (49%) of those who reported recent methamphetamine use obtained an SDS score of ≥ 4 , while 59% of participants reporting recent opioid use obtained a score of ≥ 5 , indicating possible dependence on these substances.

Almost two fifths (37%) of the sample reported that they were in any drug treatment for their substance use in 2024 (39% in 2023), with the most common treatment being methadone (19%).

In 2024, 53% of participants reported that they had received a hepatitis C virus (HCV) antibody test in the past year, stable relative to 2023 (52%). Four per cent reported having a current

HCV infection (7% in 2023) and 6% reported that they had received HCV treatment in the past year (8% in 2023; $p=0.039$). Almost one third (30%) of the sample reported having had a test for human immunodeficiency virus in the past six months, stable relative to 2023 (33%).

Sexual activity, mental health and health service access

Forty-four per cent of the sample reported engaging in sexual activity in the past four weeks and one quarter (23%) reported recently having a sexual health check-up.

Self-reported mental health problems remained stable in 2024 (53%), although remained at the highest per cent reported since monitoring commenced. Three fifths (59%) reported high/very high psychological distress in 2024 (55% in 2023).

Most participants (84%) reported accessing any health service for alcohol and/or drug support in the six months preceding interview in 2024 (89% in 2023; $p=0.010$).

Driving, contact with police and modes of purchasing drugs

Seventy-seven per cent of those who had recently driven reported driving within three hours of consuming an illicit or non-prescribed drug in the past six months (70% in 2023) and 9% reported driving while over the perceived legal limit of alcohol (8% in 2023).

One third (32%) of participants reported a drug-related encounter with police which did not result in charge or arrest, stable relative to 2023 (36%). In 2024, the most popular means of arranging the purchase of illicit or non-prescribed drugs in the 12 months preceding interview was face-to-face (85%; 79% in 2023; $p=0.004$).

2024 SAMPLE CHARACTERISTICS




In 2024, 884 participants, recruited from all capital cities across Australia, were interviewed.



47 years **Male**

The median age in 2024 was 47, and 69% identified as male.




In the 2024 sample, 89% were unemployed and 20% had no fixed address.


- Injected heroin**
- Injected methamphetamine**
- Injected other illicit or non-prescribed drugs**

Participants were recruited on the basis that they had injected drugs at least monthly in the previous 6 months.


INJECTING-RELATED RISKS AND HARMS




In 2024, 5% of participants reported receptive sharing in the past month, and 9% reported distributive sharing.



Percentage who reported re-using their own needles in the past month.




Percentage who reported injecting someone else after injecting themselves in the past month.




29% of participants reported having an injection-related health issue in the past month, stable from 2023 (26%).

OTHER HARMS




In 2024, 63% reported using two or more drugs on the day preceding interview: the most commonly used combination of drug classes was stimulants and cannabis (19%).



Past year non-fatal overdose remained stable in 2024 relative to 2023.




In 2024, 53% of participants reported a mental health problem in the 6 months preceding interview.



Among those who reported a mental health problem, the three most common mental health issues were depression, anxiety and PTSD.


NALOXONE AND OTHER HARM REDUCTION STRATEGIES




Knowledge of take-home naloxone and past year naloxone access remained stable in 2024.



Among those who were aware of naloxone, 27% reported ever using naloxone to resuscitate someone who had overdosed, with 17% having done so in the past year.



Percentage who reported that they or someone else had tested the content and/or purity of their illicit drugs in Australia in the past year.




Percentage who reported current drug treatment and health service access for AOD support in the past six months.


HEROIN




Past 6 month use of heroin remained stable in 2024 (51%) relative to 2023 (56%).



Of those who had recently consumed heroin, 75% reported weekly or more frequent use, stable from 2023 (75%).




The median reported price for a point of heroin.




Percentage who perceived heroin as being 'easy' or 'very easy' to obtain.

METHAMPHETAMINE


FORM of methamphetamine




Past 6 month use remained stable in 2024 relative to 2023.



Of those who had recently used any form of methamphetamine, 78% reported weekly or more frequent use, stable from 2023 (75%).




The median reported price for a point of crystal methamphetamine.




Percentage who perceived crystal methamphetamine as being 'easy' or 'very easy' to obtain.

CANNABIS AND/OR CANNABINOID-RELATED PRODUCTS




Past 6 month use remained stable in 2024 (69%) relative to 2023 (69%).



Of those who had recently used non-prescribed cannabis/cannabinoid-related products, 55% reported daily use, stable from 2023 (51%).




Of participants who had consumed non-prescribed cannabis and/or cannabinoid-related products in the last 6 months, 95% had smoked it.




Percentage who perceived cannabis/cannabinoid-related products as being 'easy' or 'very easy' to obtain (stable from 2023).

PAST 6 MONTH USE OF OTHER DRUGS


Non-prescribed morphine




Non-prescribed fentanyl



Non-prescribed pegabalin



GHB/GBL/1,4-BD



1

Background and Methods

The Illicit Drug Reporting System (IDRS) interviews are conducted annually with a sentinel cross-sectional group of people who regularly inject drugs, recruited from all capital cities of Australia (N=884 in 2024). The results from the IDRS interviews are not representative of all people who consume drugs, nor of illicit drug use in the general population, but this is not the aim of these data. Rather, these data are intended to provide evidence indicative of trends that warrant further monitoring. These findings should be interpreted alongside analyses of other data sources for a more complete profile of trends in illicit drug use, market features, and harms in Australia.

Background

The [Illicit Drug Reporting System \(IDRS\)](#) is an ongoing illicit drug monitoring system which has been conducted in all states and territories of Australia since 2000, and forms part of [Drug Trends](#). The purpose of the IDRS is to provide a coordinated approach to monitoring the use, market features, and harms of illicit drugs.

The IDRS is designed to be sensitive to emerging trends, providing data in a timely manner, rather than describing issues in extensive detail. It does this by studying a range of data sources, including data from annual interviews with people who regularly inject illicit/non-prescribed drugs and from secondary analyses of routinely-collected indicator data. This report focuses on the key results from the annual interview component of the IDRS.

Methods

IDRS 2000-2019

Full details of the [methods for the annual interviews](#) are available for download. To briefly summarise, participants were recruited using multiple methods (e.g., needle and syringe programs (NSP) and peer referral) and needed to: i) be at least 17 years of age (due to ethical requirements); ii) have injected psychoactive non-prescribed or illicit drugs at least six days during the six months preceding interview; and iii) have been a resident of the capital city in which the interview took place for ten of the past 12 months. Interviews took place in varied locations negotiated with participants (e.g., treatment services, coffee shops or parks), and in the latter years were conducted using REDCap (Research Electronic Data Capture), a software program to collect data on laptops or tablets. Following provision of written informed consent and completion of a structured interview, participants were reimbursed \$40 cash for their time and expenses incurred.

IDRS 2020-2024: COVID-19 Impacts on Recruitment and Data Collection

Given the emergence of COVID-19 and the resulting restrictions on travel and people's movement in Australia (which first came into effect in March 2020), face-to-face interviews were not always possible due to the risk of infection transmission for both interviewers and participants. For this reason, all methods in 2020 were similar to previous years as detailed above, with the exception of:

1. Means of data collection: Interviews were conducted via telephone across all capital cities in 2020, with some capital cities (Darwin, Northern Territory (NT) and Hobart, Tasmania (TAS)) also offering face-to-face interviews;
2. Means of consenting participants: Participants' consent to participate was collected verbally prior to beginning the interview;
3. Means of reimbursement: Participants were given the option of receiving \$40 reimbursement via one of three methods, comprising bank transfer, PayID or gift voucher, where completing the interview via telephone; and
4. Age eligibility criterion: Changed from 17 years old (16 years old in Perth, Western Australia (WA)) to 18 years old.

From 2021 onwards, a hybrid approach was used whereby interviews were conducted face-to-face (with participants reimbursed with cash) or via telephone/videoconference (with participants reimbursed via bank transfer or other electronic means). Face-to-face interviews were the preferred methodology, however telephone interviews were conducted when required (i.e., in accordance with government directives) or when requested by services. Consent was collected verbally for all participants.

In 2023, there was considerable difficulty in recruiting participants from Darwin, despite extensive recruitment efforts. Although it is difficult to provide a definitive reason for this, it seems that this was reflective of a disruption to the drug markets in Darwin, with fewer clients entering the recruitment sites (i.e., Needle and Syringe Programs in Darwin and Palmerston) during the recruitment period than has been observed in previous years. Similar impacts were also observed in other research projects, with the [Australian Needle and Syringe Program Survey](#) recruiting 20 people who inject drugs from three sites in Darwin, Palmerston and Alice Springs in 2022 (compared to 85 people in 2019). Data from the NT IDRS are included in the national estimates but are not presented individually in jurisdictional tables for 2023 due to small numbers ($n < 50$) reporting.

2024 IDRS Sample

Between 1 June-12 July 2024, a total of 884 participants were recruited across capital cities nationally. The number of participants recruited from the capital city in each jurisdiction were: Sydney, NSW, $n=150$; Melbourne, VIC, $n=150$; Adelaide, SA, $n=106$; Canberra, ACT, $n=100$; Hobart, TAS, $n=102$; Brisbane and Gold Coast, QLD, $n=103$; Darwin, NT, $n=70$; and Perth, WA, $n=103$. Ten per cent ($n=93$) of all 2024 interviews were conducted via telephone/videoconference: Canberra, ACT $n=7$, Sydney, NSW $n=1$, Darwin, NT $n=2$, Adelaide, SA $n=5$; Hobart, TAS $n=16$; and Perth, WA $n=62$.

In 2024, recruitment methods remained stable compared to 2023, whereby most participants continued to be recruited via needle and syringe programs (NPSs) (51%; 53% in 2023) and word-of-mouth (41%; 39% in 2023). Few participants (2%) were recruited via a treatment provider (7% in 2023) and fewer recruited by other methods such as social media (2%; 0% in 2023). One fifth (22%) of the 2024 sample had taken part in the 2023 interview (21% of the 2023 sample had taken part in the 2022 interview; $p=0.813$).

Data Analysis

For normally distributed continuous variables, means and standard deviations (SD) are reported; for skewed data (i.e., skewness $> \pm 1$ or kurtosis $> \pm 3$), medians and interquartile ranges (IQR) are reported. Tests of statistical significance have been conducted between estimates for 2023 and 2024. Note that no corrections for multiple comparisons have been made and thus comparisons should be treated with caution. Values where cell sizes are ≤ 5 have been suppressed with corresponding notation (zero values are reported). References to 'recent' use and behaviours refers to the six months preceding interview. The response options 'Don't know' and 'Skip question', which were available to select throughout the interview, were excluded from analysis.

Guide to Table/Figure Notes

Table 1: Guide to Table/Figure Notes

Legend	
	Empty cell(s) indicates question not asked in respective year (for figures)
/	Question not asked in respective year (for tables)
-	Per cent suppressed due to small cell size ($n \leq 5$ but not 0) (for figures and tables)
*$p < 0.050$; **$p < 0.010$; ***$p < 0.001$	Statistical significance between 2023 and 2024
Syd	Sydney
Can	Canberra
Mel	Melbourne
Hob	Hobart
Ade	Adelaide
Per	Perth
Dar	Darwin
Bri/GC	Brisbane and the Gold Coast (and the Sunshine Coast 2014-16)

Interpretation of Findings

Caveats to interpretation of findings are discussed more completely in the [methods for the annual interviews](#) but it should be noted that these data are from participants recruited in capital cities, and thus do not reflect trends in regional and remote areas. Further, the results are not representative of all people who consume illicit drugs, nor of illicit drug use in the general population, but rather are intended to provide evidence indicative of emerging issues that warrant further monitoring.

This report covers a subset of items asked of participants and does not include jurisdictional-level results beyond estimates of recent use of various substances (comprehensive jurisdictional findings are provided separately; see below), nor does it include implications of findings. These findings should be interpreted alongside analyses of other data sources for a more complete profile of trends in illicit drug use, market features, and harms in Australia (see section on 'Additional Outputs' below for details of other outputs providing such profiles).

Additional Outputs

[Infographics](#) from this report are available for download. There are a range of outputs from the IDRS which triangulate key results from the annual interviews and other data sources and consider the implications of these findings, including [national reports](#), [jurisdictional reports](#), [bulletins](#), and other resources available via the [Drug Trends webpage](#). This includes results from the [Ecstasy and Related Drugs Reporting System \(EDRS\)](#), which focuses on the use of ecstasy and other illicit stimulants.

Please contact the research team at drugtrends@unsw.edu.au with any queries, to request additional analyses using these data, or to discuss the possibility of including items in future interviews.

2

Sample Characteristics

Participants were asked questions about select sociodemographic characteristics, as well as key drug use characteristics of interest.

Sample Characteristics

In 2024, the median age of the sample was 47 years (IQR=40-53; 46 years in 2023; IQR=40-52; $p=0.085$). Gender remained stable compared to 2023 ($p=0.447$), with two thirds (69%) of the sample identifying as male (68% in 2023) (Table 2). In 2024, current employment status remained stable relative to 2023 ($p=0.191$), with most participants reporting that they were unemployed at the time of the interview (89%; 86% in 2023). The median weekly income significantly increased from \$400 (IQR=335-500) in 2023 to \$424 (IQR=350-550) in 2024 ($p=0.006$). Current accommodation type remained stable between 2023 and 2024 ($p=0.461$), with most participants reporting living in their own house/flat (66%; 65% in 2023). One fifth (20%) reported having 'no fixed address' in 2024 (19% in 2023), followed by 6% reporting living in a boarding house/hostel (6%; 5% in 2023) and 5% in parent's/family home (6% in 2023).

In 2024, drug of choice remained stable compared to 2023 ($p=0.057$), with two fifths (42%) of the sample nominating methamphetamine as their drug of choice (45% in 2023), followed by another two fifths (39%) nominating heroin (41% in 2023) as their drug of choice (Figure 1). The drug injected most often in the past month also remained stable in 2024 relative to 2023 ($p=0.476$), with methamphetamine reported as the drug injected most often by 59% of the sample (56% in 2023) (Figure 2), followed by heroin (34%; 37% in 2023).

Weekly or more frequent consumption of crystal methamphetamine (63% versus 60%; $p=0.183$), heroin (39% versus 42%; $p=0.219$), and non-prescribed cannabis (57% versus 56%; $p=0.661$) all remained stable in 2024 compared to 2023 (Figure 3).


Table 2: Demographic characteristics of the sample, nationally, 2023-2024, and by capital city, 2024

	National		Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/ GC
	N=820	N=884	N=150	N=100	N=150	N=102	N=106	N=103	N=70	N=103
	2023	2024	2024	2024	2024	2024	2024	2024	2024	2024
Median age (years; IQR)	46 (40-52)	47 (40-53)	48 (40-54)	48 (40-54)	48 (42-54)	45 (40-52)	48 (40-54)	46 (39-53)	49 (40-53)	43 (38-48)
% Gender										
Female	31	30	26	28	27	33	38	31	37	25
Male	68	69	73	70	72	67	61	69	61	75
Non-binary	-	-	-	-	-	0	-	0	-	0
% Aboriginal and/or Torres Strait Islander	26	28	36	29	20	22	29	17	51	25
% Born in Australia	89	88	89	87	86	97	91	81	94	84
% English primary language spoken at home	97	96	93	97	95	99	95	98	100	98
% Sexual identity										
Heterosexual	85	85	79	90	89	89	80	90	81	78
Homosexual	4	4	7	-	-	-	-	5	-	8
Bisexual	9	9	12	7	6	6	16	-	16	10
Queer	1	1	-	0	-	-	-	0	-	0
Other	1	2	-	-	-	-	-	-	0	-
Mean years of school education (range)	10 (0-12)	10 (1-12)	10 (5-12)	10 (4-12)	10 (2-12)	10 (7-12)	10 (4-12)	10 (3-12)	10 (7-12)	10 (1-12)
% Post-school qualification(s)^	61	62	58	65	60	66	66	59	56	71
% Current employment status										
Unemployed	86	89	93	91	94	88	92	82	86	85
Employed full time	3	3	-	-	-	-	-	10	-	-
Part time/casual	7	6	5	7	-	7	-	5	11	8
Self-employed	3	2	-	-	-	-	-	-	0	-
Other	0	1	-	0	-	0	0	-	0	-
% Past month gov't pension, allowance or benefit	93	94	98	94	95	97	92	87	94	90
Current median weekly income (\$; IQR)	400 (335-500)	424** (350-550)	390 (325-500)	430 (350-543)	450 (369-550)	448 (356-550)	400 (350-500)	450 (354-600)	450 (350-550)	428 (359-550)
% Current accommodation										
Own home (incl. renting)	65	66	74	76	63	64	65	58	66	62
Parents'/family home	6	5	-	8	-	8	5	12	9	6

	National		Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/ GC
	N=820	N=884	N=150	N=100	N=150	N=102	N=106	N=103	N=70	N=103
	2023	2024	2024	2024	2024	2024	2024	2024	2024	2024
Boarding house/hostel	5	6	9	-	9	-	-	-	9	7
Shelter/refuge	3	2	-	-	-	-	0	7	0	0
No fixed address	19	20	16	12	25	17	26	19	14	25
Other	1	1	0	-	-	-	-	0	-	0


Note. ^Includes trade/technical and university qualifications. Statistical significance for 2023 versus 2024 is presented in table for national estimates; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. For sample characteristics over the whole duration of the project, see [methods for the annual interviews](#). Please refer to Table 1 for a guide to table/figure notes.

Figure 1: Drug of choice, nationally, 2000-2024




Note. Participants could only endorse one substance. Substances listed in this figure are the primary endorsed; a nominal per cent endorsed other substances. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 2: Drug injected most often in the past month, nationally, 2000-2024



Note. Participants could only endorse one substance. Substances listed in this figure are the primary endorsed; a nominal per cent endorsed other substances. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 3: Weekly or more frequent substance use in the past six months, nationally, 2000-2024



Note. Computed of the entire sample regardless of whether they had used the substance in the past six months. Prior to 2021, we did not distinguish between prescribed and non-prescribed cannabis, and as such it is possible that 2017-2020 figures include some participants who were using prescribed cannabis only (with medicinal cannabis first legalised in Australia in November 2016), although we anticipate these numbers would be very low. Further, from 2022, we captured use of 'cannabis and/or cannabinoid-related products', while in previous years questions referred only to 'cannabis'. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

3

Heroin

Participants were asked about their recent (past six month) use of heroin and homebake heroin. Participants typically describe heroin as white/off-white rock, brown/beige rock or white/off-white powder. Homebake is a form of heroin made from pharmaceutical products and involves the extraction of diamorphine from pharmaceutical opioids such as codeine and morphine.

Patterns of Consumption

Recent Use (past 6 months)

There has been some fluctuation in recent use of any heroin over time. In 2024, 51% of the national sample reported recent use of heroin (56% in 2023; $p=0.076$) (Figure 4). Recent use of heroin remained stable in all capital city samples (Table 3).

Frequency of Use

Among those who reported recent heroin use and commented ($n=454$), the median frequency of use was equivalent to every second day in the past six months (median 90 days; IQR=24-180), stable relative to 2023 (90 days; IQR=21-180; $n=457$; $p=0.366$) (Figure 4). Weekly or more frequent use among those who reported recent use was also stable in 2024 (75%) compared to 2023 (75%; $p=0.812$), as was daily use (38%; 34% in 2023; $p=0.246$).

Routes of Administration

Injecting remained the most common route of administration among participants who consumed heroin in 2024 (99%; 98% in 2023; $p=0.773$). Participants who reported injecting did so on a median of 90 days (IQR=24-180), stable relative to 2023 (90 days; IQR=24-180; $p=0.367$). Fewer participants reported smoking (6%; 7% in 2023; $p=0.498$) and snorting ($n\leq 5$; $n\leq 5$ in 2023).


Quantity

Of those who reported recent use and responded ($n=425$), the median amount of heroin used on a 'typical' day in the last six months was 0.20 grams (IQR=0.10-0.30; 0.20 grams in 2023; IQR=0.10-0.30; $n=434$; $p=0.290$). The median maximum amount of heroin used per day in the last six months was 0.30 grams (IQR=0.10-0.80; $n=428$; 0.40 grams in 2023; IQR=0.20-0.70; $n=432$; $p=0.201$).

Forms Used

Among participants who reported recent use of heroin and commented ($n=451$), two thirds (66%) reported using white/off-white rock heroin, stable relative to 2023 (65%; $p=0.315$), and 53% reported using white/off-white powder heroin, a significant decrease from 59% in 2023 ($p=0.015$). One quarter (26%) reported using brown/beige rock, a significant decrease relative to 2023 (35%; $p<0.001$), and similarly, one quarter (25%) reported using brown/beige powder, also a significant decrease compared to 2023 (32%; $p=0.003$). Two per cent reported using homebake in 2024, stable relative to 2023 (3%; $p=0.389$). No participants reported using purple rock or purple powder in 2024 or 2023.

Figure 4: Past six month use and frequency of use of heroin, nationally, 2000-2024



Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 3: Past six month use of heroin, by capital city, 2000–2024

%	Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
2000	95	92	97	38	73	80	56	86
2001	96	83	90	24	65	55	36	62
2002	96	89	94	21	48	64	22	81
2003	97	88	90	26	55	63	16	64
2004	95	91	86	19	60	69	34	79
2005	88	86	89	19	61	69	24	64
2006	81	71	76	9	60	53	12	63
2007	88	72	85	-	67	57	7	65
2008	83	86	85	-	51	59	14	74
2009	94	78	79	12	72	71	13	75
2010	92	78	85	8	64	69	5	81
2011	87	79	81	19	57	79	9	65
2012	89	74	84	9	52	80	11	65
2013	83	75	83	10	41	75	17	72
2014	85	75	83	13	43	79	7	66
2015	91	79	74	-	49	75	14	50
2016	86	70	77	7	37	78	7	58
2017	80	74	80	15	52	66	13	55
2018	83	75	83	8	35	67	9	45
2019	82	77	85	15	28	62	-	63
2020	78	85	86	24	47	69	-	64
2021	75	78	76	11	23	61	-	43
2022	72	66	78	22	35	60	-	51
2023	67	81	87	11	22	63	~	46
2024	73	74	83	12	21	70	-	38

Note. ~Due to the particularly small samples recruited in Darwin in 2023 (n<50), data are not presented in this table. Statistical significance for 2023 versus 2024 is presented in table; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Price, Perceived Purity and Perceived Availability

Price

In 2024, the price of heroin (per cap, point and gram) remained stable relative to 2023. The reported median price for heroin was \$325 for one gram (IQR=228-430; n=38; \$350 in 2023; IQR=250-450; n=37; $p=0.351$) and \$80 per point (0.10 of a gram) (IQR=50-100; n=235; \$80 in 2023; IQR=50-100; n=229; $p=0.404$). The median price per cap has remained relatively stable over the years, with a median price of \$50 per cap in 2024 (IQR=50-50; n=41; \$50 in 2023; IQR=50-50; n=33; $p=0.805$) (Figure 5).


Perceived Purity

Among those who were able to comment in 2024 (n=414), there was no significant change in the perceived purity of heroin relative to 2023 ($p=0.324$). Almost two fifths (39%) perceived the purity of heroin to be 'medium' in 2024 (35% in 2023), 30% reported 'high' (28% in 2023) purity, and one fifth (20%) reported 'low' (25% in 2023) purity (Figure 6). The per cent reporting the perceived purity of heroin as 'high' in 2024 was the highest since monitoring commenced.

Perceived Availability


Among those who were able to comment in 2024 (n=434), perceived availability of heroin remained stable, relative to 2023 ($p=0.995$). Most participants perceived heroin to be 'very easy' (55%; 56% in 2023) to obtain, and one third (36%) reported that it was 'easy' (35% in 2023) to obtain. Seven per cent perceived it to be 'difficult' to obtain (7% in 2023) (Figure 7).

Figure 5: Median price of heroin per cap, point and gram, nationally, 2000-2024




Note. Among those who commented. Between 2009-2017 a cap was referred to as cap/point (thus, the same values appear for cap and point during this period); in 2018 these measures were separated out into their own response options. The error bars represent the IQR. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 6: Current perceived purity of heroin, nationally, 2000-2024



Note. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 7: Current perceived availability of heroin, nationally, 2000-2024



Note. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

4

Methamphetamine

Participants were asked about their recent (past six month) use of various forms of methamphetamine, including powder (white particles, described as speed), base (wet, oily powder) and crystal (clear, ice-like crystals).

Patterns of Consumption (Any Methamphetamine)

Recent Use (past 6 months)

Recent use of any methamphetamine (powder, base and crystal) peaked in 2003 (89%), before declining to 60% in 2010. In the following years, the per cent of participants reporting recent use of any methamphetamine has been gradually increasing. In 2024, 82% reported recent use, the highest per cent since 2003, although stable from 2023 (81%; $p=0.757$) (Figure 8). Consistent with previous years, any recent methamphetamine use remained high across all capital city samples, with a significant increase in the per cent reporting recent any methamphetamine use in the Brisbane/Gold Coast (85%; 73% in 2023; $p=0.030$) and Perth (65%; 79% in 2023; $p=0.044$) samples (Table 4).

Frequency of Use

In 2024, participants reported using methamphetamine on a median of 72 days (i.e. three times per week; IQR=24-170; $n=722$), stable relative to 2023 (72 days; IQR=24-160; $n=664$; $p=0.174$) (Figure 9). Weekly or more frequent use, among those who reported recent use, also remained stable in 2024 (78%; 75% in 2023; $p=0.185$), as did the per cent reporting daily use (24%; 22% in 2023; $p=0.477$).


Forms Used

The forms of methamphetamine used by participants have shifted over time, with use of powder and base methamphetamine decreasing and use of crystal methamphetamine increasing (Figure 8). Among those who reported recent use of any methamphetamine ($n=725$) in 2024, nearly the entire sample (99%; 99% in 2023) reported using crystal methamphetamine, followed by 10% reporting powder methamphetamine (13% in 2023; $p=0.155$) and 6% reporting base methamphetamine (6% in 2023; $p=0.907$).

Number of Forms Used


Among participants who had recently consumed any methamphetamine and commented ($n=725$), the median number of forms of methamphetamine used was one (IQR=1-1) in 2024, stable from 2023 (1 form; IQR=1-1; $n=666$; $p=0.467$). This was consistent across jurisdictions.

Figure 8: Past six month use of any methamphetamine and of methamphetamine powder, base, and crystal, nationally, 2000-2024



Note. 'Any methamphetamine' includes crystal, powder, base and liquid methamphetamine combined from 2000-2018, and crystal, powder and base methamphetamine combined from 2019 onwards. Questions regarding liquid methamphetamine not asked from 2019. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 9: Frequency of use of any methamphetamine and of methamphetamine powder, base, and crystal, nationally, 2000-2024



Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Y axis reduced to 80 days to improve visibility of trends. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 4: Past six month use of any methamphetamine, by capital city, 2000–2024

%	Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
2000	40	68	53	83	52	85	74	71
2001	51	82	76	85	81	92	70	83
2002	48	70	73	84	85	85	72	81
2003	53	71	79	88	72	90	71	89
2004	56	81	71	91	71	85	70	81
2005	58	73	79	95	78	75	72	78
2006	72	92	81	83	78	86	64	82
2007	62	83	74	88	74	70	68	78
2008	74	74	68	74	69	74	57	59
2009	57	75	70	80	61	63	55	70
2010	57	59	60	70	74	64	36	59
2011	60	73	65	77	66	64	55	71
2012	72	77	67	77	79	72	48	53
2013	75	66	61	74	75	72	43	58
2014	75	76	77	70	75	66	37	72
2015	66	81	74	72	76	71	67	67
2016	77	83	73	75	77	65	71	70
2017	69	80	66	69	76	70	66	74
2018	76	85	78	79	83	67	75	72
2019	76	79	70	81	90	79	90	68
2020	77	65	66	77	81	73	83	63
2021	74	75	79	89	88	82	76	79
2022	87	81	75	84	90	78	80	70
2023	86	75	77	88	91	79	~	73
2024	83	85	70	91	96	65*	87	85*

Note. ~Due to the particularly small samples recruited in Darwin in 2023 (n<50), data are not presented in this table. Statistical significance for 2023 versus 2024 is presented in table; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Patterns of Consumption (by form)

Methamphetamine Powder

Recent Use (past 6 months): Use of methamphetamine powder has decreased over time. In 2024, 8% reported recent use, the lowest per cent recorded since monitoring began, though stable relative to 2023 (10%; $p=0.184$) (Figure 8). The per cent reporting recent use significantly decreased in the Melbourne ($n\leq 5$; 7% in 2023; $p=0.020$) and Perth ($n\leq 5$; 10% in 2023; $p=0.046$) samples (Table 5).

Frequency of Use: Frequency of use remained stable in 2024 at a median of 17 days (IQR=4-72; $n=72$; 18 days in 2023; IQR=5-72; $n=83$; $p=0.897$) (Figure 9). In 2024, nearly half (49%) of those who had recently used methamphetamine powder reported weekly or more frequent use, stable from 47% in 2023 ($p=0.870$).

Routes of Administration: Most (96%) participants who had recently used methamphetamine powder reported injecting powder in the past six months, stable relative to 2023 (92%; $p=0.340$). Participants who reported injecting methamphetamine powder did so on a median of 22 days (IQR=4-72), stable relative to 2023 (20 days; IQR=6-72; $p=0.746$). One fifth (22%) reported smoking powder methamphetamine in 2024, stable relative to 2023 (27%; $p=0.456$).

Quantity: Of those who reported recent use and responded ($n=70$), the median amount of powder used on a 'typical' day in the past six months was 0.20 grams (IQR=0.10-0.50; 0.20 grams in 2023; IQR=0.10-0.50; $n=78$; $p=0.738$).

The median maximum amount of powder used per day in the last six months was 0.50 grams (IQR=0.20-0.60; $n=66$; 0.40 grams in 2023; IQR=0.20-0.70; $n=78$; $p=0.723$).

Methamphetamine Base

Recent Use (past 6 months): Base has typically been the least commonly used form of methamphetamine since monitoring commenced in 2001 and has gradually declined over time. The per cent of participants reporting recent use of base remained stable at 5% in 2024 (5% in 2023; $p=0.908$) (Figure 8). Recent use remained low and stable across all capital city samples in 2024 (Table 6).

Frequency of Use: Participants reported using base on a median of four days in the preceding six months (IQR=2-13; $n=42$; 6 days in 2023; IQR=2-38; $n=40$; $p=0.319$) (Figure 9).

Routes of Administration: Injecting was the most common route of administration reported by participants who had recently used methamphetamine base (95%; 85% in 2023), with few participants reporting smoking ($n\leq 5$; 17% in 2023). Due to small numbers reporting recent use, significance testing for routes of administration were not undertaken.

Quantity: Of those who reported recent use and responded ($n=38$), the median amount of base used on a 'typical' day in the past six months was 0.30 grams (IQR=0.20-0.50; 0.20 grams in 2023; IQR=0.10-0.50; $n=38$; $p=0.305$). The median maximum amount of base used per day in the last six months was 0.50 grams (IQR=0.20-0.80; $n=38$; 0.30 grams in 2023; IQR=0.20-0.70; $n=37$; $p=0.272$).

Methamphetamine Crystal

Recent Use (past 6 months): Reports of recent use of methamphetamine crystal have been increasing since 2009 (Figure 8), surpassing powder methamphetamine from 2012 onwards. In 2024, 81% of the national sample reported recent use of methamphetamine crystal, the highest per cent observed since monitoring commenced in 2000, although stable from 2023 (80%; $p=0.762$). A significant decrease in methamphetamine crystal was observed in the Perth sample (65%; 79% in 2023; $p=0.044$), and, conversely, a significant increase was observed in the Brisbane/Gold Coast sample (85%; 70% in 2023; $p=0.007$) (Table 7).

Frequency of Use: Median days of use remained stable in 2024 at 72 days (IQR=24-170; $n=711$; 72 days in 2023; IQR=21-155; $n=656$; $p=0.199$), the highest median frequency for the second year running since monitoring commenced (Figure 9). Almost four fifths (78%) of those who had recently used

crystal methamphetamine reported weekly or more frequent use (75% in 2023; $p=0.151$), and almost one quarter (24%) reported daily use (22% in 2023; $p=0.473$).

Routes of Administration: Consistent with previous years, the most common route of administration was injecting (97%; 96% in 2023; $p=0.768$). Participants who reported injecting did so on a median of 72 days in the preceding six months (IQR=24-150), stable relative to 2023 (72 days; IQR=18-140; $p=0.222$). Two fifths (41%) reported smoking crystal methamphetamine 2024, stable relative to 2023 (41%; $p=0.957$).

Quantity: Of those who reported recent use and responded ($n=698$), the median amount of crystal used on a 'typical' day of consumption in the past six months was 0.20 grams (IQR=0.10-0.30; 0.20 grams in 2023; IQR=0.10-0.30; $n=638$; $p=0.709$). The median maximum amount of crystal used per day in the last six months was 0.30 grams (IQR=0.20-0.60; $n=692$; 0.30 grams in 2023; IQR=0.20-0.50; $n=634$; $p=0.348$).

Table 5: Past six month use of powder methamphetamine, by capital city, 2000-2024

%	Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
2000	32	63	49	77	51	81	70	58
2001	42	63	74	45	47	87	63	80
2002	39	51	70	35	56	77	67	55
2003	31	48	70	51	53	71	60	58
2004	35	41	65	60	44	61	60	61
2005	38	59	75	76	39	61	69	65
2006	49	58	71	54	39	66	57	54
2007	35	55	65	63	42	61	58	62
2008	38	37	64	61	34	61	50	35
2009	33	46	65	56	33	54	50	46
2010	29	48	53	56	29	51	25	41
2011	30	46	49	67	36	43	43	40
2012	17	42	39	70	34	45	46	30
2013	14	29	23	61	40	48	31	37
2014	17	36	25	50	34	39	16	31
2015	13	15	18	49	32	34	25	27
2016	17	18	9	33	19	18	24	27
2017	10	20	15	30	18	16	19	34
2018	11	23	16	22	31	12	17	34
2019	13	27	11	35	44	26	15	20
2020	11	13	10	43	35	36	-	19
2021	-	13	7	16	34	9	-	19
2022	11	-	5	18	31	13	-	11
2023	7	10	7	14	23	10	~	7
2024	12	9	-*	13	15	-*	-	10

Note. ~Due to the particularly small samples recruited in Darwin in 2023 (n<50), data are not presented in this table. Statistical significance for 2023 versus 2024 is presented in table; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.005$. Please refer to Table 1 for a guide to table/figure notes.

Table 6: Past six month use of base methamphetamine, by capital city, 2001-2024

%	Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
2001	23	36	32	52	59	56	18	75
2002	23	30	20	74	65	56	21	42
2003	32	13	18	46	51	40	30	50
2004	31	25	11	72	46	45	26	60
2005	38	28	13	79	61	54	16	40
2006	43	32	15	55	52	37	25	53
2007	41	32	8	48	42	22	20	48
2008	33	18	5	25	37	13	10	34
2009	36	21	13	55	31	12	16	41
2010	29	18	3	40	43	8	6	30
2011	17	17	11	39	35	6	12	37
2012	15	15	11	43	32	6	7	21
2013	12	6	3	17	31	11	7	22
2014	12	-	3	19	30	8	-	22
2015	6	10	4	9	26	-	-	20
2016	11	5	0	-	24	-	6	14
2017	8	11	3	-	30	7	7	20
2018	9	8	-	-	8	-	10	14
2019	8	8	-	-	24	-	-	16
2020	4	-	-	8	28	8	-	10
2021	-	8	0	-	-	0	-	8
2022	5	-	-	-	10	-	0	-
2023	6	10	-	-	13	-	~	-
2024	7	-	0	-	17	-	-	-

Note. Base asked separately from 2001 onwards. ~Due to the particularly small samples recruited in Darwin in 2023 (n<50), data are not presented in this table. Statistical significance for 2023 versus 2024 is presented in table; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 7: Past six month use of crystal methamphetamine, by capital city, 2000-2024

%	Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
2000	14	17	9	6	11	51	6	13
2001	29	72	52	56	58	85	24	75
2002	25	34	26	20	56	74	20	39
2003	38	65	50	69	48	80	34	60
2004	45	73	41	52	48	83	32	51
2005	38	62	29	50	46	68	21	36
2006	57	88	53	56	49	76	29	55
2007	50	80	43	38	41	56	29	39
2008	69	68	39	32	49	61	28	40
2009	46	57	32	26	30	43	15	46
2010	48	48	36	20	60	40	18	37
2011	53	57	53	26	44	46	28	50
2012	68	66	59	43	56	64	26	44
2013	74	61	55	45	57	59	30	50
2014	74	72	75	54	60	53	26	58
2015	65	79	71	59	70	64	60	62
2016	77	78	73	73	73	75	62	69
2017	69	79	63	65	72	69	60	69
2018	76	85	77	76	79	64	74	70
2019	74	77	68	76	89	75	87	65
2020	75	63	64	77	80	69	83	63
2021	74	74	78	85	83	80	74	78
2022	87	81	75	84	83	77	80	70
2023	86	74	77	85	88	79	~	70
2024	82	83	70	89	92	65*	87	85**

Note. ~Due to the particularly small samples recruited in Darwin in 2023 (n<50), data are not presented in this table. Statistical significance for 2023 versus 2024 is presented in table; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Price, Perceived Purity and Perceived Availability

Methamphetamine Powder

Price: The median price for one point (0.10 of a gram) of methamphetamine powder remained stable in 2024 (\$50; IQR=50-50; n=45; \$50 in 2023; IQR=50-50; n=46; $p=0.630$), as did the median price for one gram of methamphetamine powder (\$160; IQR=150-300; n=5 in 2023; $p=0.892$) (Figure 10).

Perceived Purity: Among those who responded in 2024 (n=94), the perceived purity of powder remained stable relative to 2023 ($p=0.177$). Almost one third (30%) of participants perceived purity to be 'medium' (36% in 2023), followed by 29% reporting 'low' (15% in 2023) purity and 26% reporting 'high' (29% in 2023) purity (Figure 12).

Perceived Availability: Among those who responded in 2024 (n=96), the perceived availability of methamphetamine powder remained stable relative to 2023 ($p=0.801$). In 2024, 49% perceived methamphetamine powder to be 'very easy' to obtain (45% in 2023), 25% perceived it to be 'easy' to obtain (27% in 2023) and 20% perceived it to be 'difficult' to obtain (18% in 2023) (Figure 14).

Methamphetamine Base

Questions pertaining to the price, perceived purity and perceived availability of methamphetamine base were not asked of participants from 2020 onwards. For historical information, please refer to the [2019 IDRS National Report](#).

Methamphetamine Crystal

Price: The median price for one point (0.10 of a gram) of crystal in 2024 was \$50 (IQR=50-50;


n=373; \$50 in 2023; IQR=50-50; n=352; $p=0.550$). Across the years, the median price for one gram of crystal has fluctuated between \$250 and \$600. In 2024, the median price for one gram of crystal was \$300 (IQR=200-450; n=58), stable relative to 2023 (\$380; IQR=300-400; n=43; $p=0.130$) (Figure 11).

Perceived Purity: Among those that were able to comment in 2024 (n=661), the perceived purity of methamphetamine crystal remained stable relative to 2023 ($p=0.625$). One third (34%) of participants perceived the purity of crystal to be 'medium' (32% in 2023) followed by 29% reporting 'high' (27% in 2023) purity. One fifth (20%) perceived the purity to be 'low' (23% in 2023), followed by 17% reporting 'fluctuating' purity (18% in 2023) (Figure 13).

Perceived Availability: Among those who commented in 2024 (n=667), the perceived availability of methamphetamine crystal remained stable relative to 2023 ($p=0.324$). Two thirds (69%) of participants perceived that crystal was 'very easy' to obtain (64% in 2023), and a further 26% perceived it to be 'easy' to obtain (30% in 2023). Five per cent perceived that crystal methamphetamine was 'difficult' to obtain (5% in 2023) (Please refer to Table 1 for a guide to table/figure notes.


Figure 15).

Figure 10: Median price of powder methamphetamine per point and gram, nationally, 2002-2024




Note. Among those who commented. The error bars represent the IQR. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 11: Median price of methamphetamine crystal per point and gram, nationally, 2001-2024




Note. Among those who commented. The error bars represent the IQR. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 12: Current perceived purity of powder methamphetamine, nationally, 2002-2024




Note. Methamphetamine asked separately for the three different forms from 2002 onwards. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 13: Current perceived purity of crystal methamphetamine, nationally, 2002-2024




Note. Methamphetamine asked separately for the three different forms from 2002 onwards. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 14: Current perceived availability of powder methamphetamine, nationally, 2002-2024



Note. Methamphetamine asked separately for the three different forms from 2002 onwards. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 15: Current perceived availability of crystal methamphetamine, nationally, 2002-2024



Note. Methamphetamine asked separately for the three different forms from 2002 onwards. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

5

Cocaine

Participants were asked about their recent (past six month) use of various forms of cocaine, including powder and crack/rock cocaine. Cocaine hydrochloride, a salt derived from the coca plant, is the most common form of cocaine available in Australia. 'Crack' cocaine is a form of freebase cocaine (hydrochloride removed), which is particularly pure. 'Crack' is most prevalent in North America and infrequently encountered in Australia.

Patterns of Consumption

Recent Use (past 6 months)

Recent use of cocaine peaked in 2001 with 35% of the sample reporting use, before subsequently declining to 11% in 2016 and stabilising thereafter. In 2024, recent use of cocaine remained stable among the national sample, with 17% reporting use in the six months preceding interview (16% in 2023; $p=0.653$) (Figure 16). The per cent reporting use in each capital city sample largely remained stable in 2024. There was, however, a significant decrease in recent use of cocaine in the Perth sample (9%; 21% in 2023; $p=0.020$) (Table 8).

Frequency of Use

Median frequency of use among the sample has varied between a median of two and eight days, with a median of two days (IQR=1-6; $n=154$) observed in 2024, stable from 2023 (2 days; IQR=1-6; $n=134$; $p=0.739$) (Figure 16). Of those who had recently used cocaine in 2024 and commented ($n=154$), 13% reported weekly or more frequent use, stable relative to 2023 (15%; $p=0.741$).

Routes of Administration

Consistent with previous years, snorting (61%; 60% in 2023; $p=0.901$) and injecting (44%; 46% in 2023; $p=0.807$) were the two most common routes of administration in 2024. Participants who reported injecting cocaine in the preceding six months had done so on a median of four days (IQR=2-8), stable relative to 2023 (3 days; IQR=1-12; $p=0.597$). The per cent who reported smoking cocaine remained low and stable at 6% (8% in 2023; $p=0.484$).


Quantity

Of those who reported recent use and responded ($n=128$), the median amount of cocaine used on a 'typical' day of consumption in the six months preceding interview was 0.40 grams (IQR=0.10-1.00; 0.20 grams in 2023; IQR=0.10-0.50; $n=101$; $p=0.139$).

Forms Used

Among participants who had recently consumed cocaine and commented ($n=153$), the vast majority reported using powder cocaine (83%; 84% in 2023; $p=0.755$), with fewer participants reporting use of crack/rock cocaine (24%) in 2024 (20% in 2023; $p=0.399$).

Figure 16: Past six month use and frequency of use of cocaine, nationally, 2000-2024



Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Secondary Y axis reduced to 10 days to improve visibility of trends. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 8: Past six month use of cocaine, by capital city, 2000-2024

%	Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
2000	63	15	13	6	20	22	18	13
2001	84	40	28	8	27	32	13	28
2002	79	18	17	12	26	17	10	15
2003	53	13	13	9	13	10	-	16
2004	47	10	10	-	6	15	10	10
2005	60	20	15	8	16	19	10	11
2006	67	8	19	12	8	10	8	9
2007	63	18	22	-	7	16	9	15
2008	58	18	24	-	-	15	-	13
2009	61	22	15	-	10	12	12	15
2010	57	6	14	-	12	15	-	13
2011	47	8	17	7	12	10	-	13
2012	44	16	9	11	7	15	-	-
2013	41	16	11	-	9	15	7	11
2014	32	15	10	8	7	7	-	9
2015	34	12	9	-	13	11	-	8
2016	25	8	10	6	6	10	-	9
2017	21	18	12	11	10	10	9	9
2018	26	14	15	11	10	12	6	9
2019	21	15	10	6	16	12	9	10
2020	23	19	17	16	14	18	-	19
2021	15	16	18	16	16	17	-	12
2022	16	17	19	14	10	12	12	17
2023	23	12	17	15	12	21	~	13
2024	29	18	14	18	13	9*	14	20

Note. ~Due to the particularly small samples recruited in Darwin in 2023 (n<50), data are not presented in this table. Statistical significance for 2023 versus 2024 is presented in table; *p<0.050; **p<0.010; ***p<0.001. Please refer to Table 1 for a guide to table/figure notes.

Price, Perceived Purity and Perceived Availability

Price

The median price for one gram of cocaine has fluctuated between \$200 and \$400 since monitoring commenced in 2000. In 2024, the median price of cocaine was reported to be \$300 for one gram (IQR=300-400; n=37), stable relative to 2023 (\$350; IQR=300-400; n=25; p=0.148). Participants reported a median of \$60 for a point/cap in 2024 (IQR=50-100; n=12), also stable relative to 2023 (\$50; IQR=50-93; n=10; p=0.537) (Figure 17).


Perceived Purity

Among those who responded in 2024 (n=98), the perceived purity of cocaine remained stable relative to 2023 (p=0.237). Fifty per cent perceived cocaine to be of 'high' purity (36% in 2023), followed by 26% perceiving it to be of 'medium' purity (35% in 2023). One fifth (20%) perceived cocaine to be of 'low' purity (22% in 2023) (Figure 18).

Perceived Availability


Among those able to comment in 2024 (n=104), the perceived availability of cocaine remained stable relative to 2023 ($p=0.978$). Two fifths (40%) reported cocaine to be 'easy' to obtain in 2024 (38% in 2023), with a further 27% reporting it to be 'very easy' to obtain (30% in 2023). One quarter (28%) perceived cocaine to be 'difficult' to obtain (28% in 2023) (Figure 19).

Figure 17: Median price of cocaine per cap/point and gram, nationally, 2000-2024




Note. Among those who commented. The error bars represent IQR. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 18: Current perceived purity of cocaine, nationally, 2000-2024



Note. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 19: Current perceived availability of cocaine, nationally, 2000-2024



Note. Statistical significance for 2023 versus 2024 is presented in figure; $p < 0.050$; $**p < 0.010$; $***p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

6

Cannabis and/or Cannabinoid-Related Products

Participants were asked about their recent (past six month) use of various forms of cannabis, including indoor-cultivated cannabis via a hydroponic system ('hydroponic'), outdoor-cultivated cannabis ('bush'), hashish, hash oil, commercially prepared edibles and CBD and THC extract.

Terminology throughout this chapter refers to **prescribed use**: use of cannabis and/or cannabinoid-related products obtained by a prescription in the person's name; **non-prescribed use**: use of cannabis and/or cannabinoid-related products which the person did not have a prescription for (i.e., illegally sourced or obtained from a prescription in someone else's name); and **any use**: use of cannabis and/or cannabinoid-related products obtained through either of the above means.

Patterns of Consumption

From 2023, participants were asked about their use of both prescribed and non-prescribed cannabis and/or cannabinoid-related products. Seven participants reported prescribed use in the six months preceding interview (n=62), a significant increase from 3% in 2023 (n=26; $p<0.001$).

In the remainder of this chapter, data from 2021-2024, and between 2000-2016, refers to non-prescribed cannabis use only, while data from 2017-2020 refers to 'any' cannabis use (including hydroponic and bush cannabis, hashish and hash oil). While comparison between 2021-2024 and previous years should be treated with caution, the relatively recent legalisation of medicinal cannabis in Australia and the small percentage reporting prescribed use in 2023 and 2024 lends confidence that estimates are relatively comparable.

Recent Use (past 6 months)

Over the course of monitoring, at least two in three participants nationally have reported recent use of non-prescribed cannabis and/or cannabinoid-related products. In 2024, 69% reported recent use of non-prescribed cannabis and/or cannabinoid-related products, stable compared to 2023 (69%; $p=0.718$) (Figure 20). The per cent reporting non-prescribed use remained high and stable across all capital city samples (Table 9).

Frequency of Use

In 2024, the median frequency of use in the past six months was 180 days (i.e., daily; IQR=50-180; n=606), stable compared to 2023 (180 days; IQR=30-180; n=566; $p=0.073$) (Figure 20). Fifty-five per cent of those who had recently used non-prescribed cannabis and/or cannabinoid-related products reported daily use (51% in 2023; $p=0.184$).

Routes of Administration

Smoking remained the most common route of administration among those who recently used non-prescribed cannabis and/or cannabinoid-related products (95%), although this was a significant decrease relative to 2023 (98%; $p=0.008$). Conversely, significantly more participants reported inhaling/vaporising (9%) and swallowing (7%) cannabis and/or cannabinoid-related products in 2024 compared to 2023 (5%; $p=0.013$ and 4%; $p=0.010$, respectively).

Quantity


Among those who reported recent use of non-prescribed cannabis and/or cannabinoid-related products and commented (n=597), the median 'typical' amount used on the last occasion of use was one gram (IQR=0.50-2.00; n=282; 1.00 gram in 2023; IQR=0.50-1.20; n=268; $p=0.184$) or three cones (IQR=2-5; n=219; 3 cones in 2023; IQR=2-5; n=208; $p=0.471$) or one joint (IQR=1-1; n=65; 1 joint in 2023; IQR=1-2; n=61; $p=0.883$).

Forms Used

Of those who had used non-prescribed cannabis and/or cannabinoid-related products in the past six months and commented (n=586), 88% reported recent use of hydroponic cannabis (88% in 2023;

$p=0.922$), and two fifths (41%) reported recent use of outdoor-grown 'bush' cannabis (41% in 2023). Smaller percentages reported having used hashish (6%; 7% in 2023; $p=0.900$), hash oil (4%; 4% in 2023; $p=0.549$), non-prescribed THC extract (4%; 2% in 2023; $p=0.075$) and non-prescribed CBD extract (2%; 1% in 2023; $p=0.293$) (Figure 21). Four per cent reported recently consuming commercially prepared edibles in 2024, a significant increase from 1% in 2023 ($p=0.006$).

Figure 20: Past six month use and frequency of use of non-prescribed cannabis and cannabinoid-related products, nationally, 2000-2024




Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Prior to 2021, we did not distinguish between prescribed and non-prescribed cannabis, and as such it is possible that 2017-2020 figures include some participants who were using prescribed cannabis only (with medicinal cannabis first legalised in Australia in November 2016), although we anticipate these numbers would be very low (in 2022 few (n≤5) people reported use of prescribed cannabis only). Further, from 2022, we captured use of 'cannabis and/or cannabinoid-related products', while in previous years questions referred only to 'cannabis'. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 9: Past six month non-prescribed use of cannabis and cannabinoid-related products, by capital city, 2000-2024

%	Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
2000	72	84	85	90	88	90	84	84
2001	83	85	88	94	85	91	81	82
2002	80	89	87	91	85	98	83	82
2003	79	86	88	88	80	81	83	76
2004	80	85	81	87	83	84	75	75
2005	80	89	86	87	80	76	79	76
2006	80	90	83	88	77	80	84	85
2007	79	83	83	87	81	69	83	84
2008	80	80	74	86	75	64	78	82
2009	79	81	79	89	61	72	79	69
2010	72	81	81	79	66	70	72	77
2011	81	87	85	78	69	71	71	79
2012	72	81	85	81	61	79	71	70
2013	80	75	80	71	61	61	67	67
2014	77	74	75	82	75	69	62	70
2015	79	81	76	73	74	60	72	60
2016	76	69	77	74	73	70	72	64
2017	79	76	71	73	73	73	59	70
2018	76	79	70	81	70	77	60	67
2019	73	79	76	76	79	72	72	65
2020	64	77	69	72	67	66	60	64
2021	65	75	66	67	67	69	59	68
2022	72	77	82	70	72	60	70	64
2023	65	75	79	73	71	66	~	59
2024	68	74	69	74	76	60	69	58

Note. ~Due to the particularly small samples recruited in Darwin in 2023 (n<50), data are not presented in this table. Prior to 2021, we did not distinguish between prescribed and non-prescribed cannabis, and as such it is possible that 2017-2020 figures include some participants who were using prescribed cannabis only (with medicinal cannabis first legalised in Australia in November 2016), although we anticipate these numbers would be very low. Further, in 2022, we captured use of 'cannabis and/or cannabinoid-related products', while in previous years questions referred only to 'cannabis'. Statistical significance for 2023 versus 2024 is presented in table; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 21: Past six month use of different forms of non-prescribed cannabis and/or cannabinoid-related products, among those who reported recent non-prescribed use, nationally, 2018-2024



Note. Prior to 2021, we did not distinguish between prescribed and non-prescribed cannabis, and as such it is possible that 2018-2020 figures include some participants who were using prescribed forms of cannabis (with medicinal cannabis first legalised in Australia in November 2016), although we anticipate these numbers would be very low. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Price, Perceived Potency and Perceived Availability

Hydroponic Cannabis

Price: Consistent with previous years, the median price per gram of hydroponic cannabis nationally was \$20 (IQR=20-25; n=144; \$20 in 2023; IQR=20-21; n=152; $p=0.319$). The price per ounce of hydroponic cannabis was \$280 in 2024 (IQR=250-323; n=48), stable from 2023 (\$290; IQR=250-345; n=42; $p=0.732$) (Figure 22A).

Perceived Potency: Among those that were able to comment in 2024 (n=444), the perceived potency of non-prescribed cannabis remained stable relative to 2023 ($p=0.092$). Two thirds (65%) perceived hydroponic cannabis to be of 'high' potency (62% in 2023) followed by 21% perceiving it to be of 'medium' potency (27% in 2023) (Figure 23A).

Perceived Availability: Among those that were able to comment in 2024 (n=447), the perceived availability of non-prescribed cannabis remained stable relative to 2023 ($p=0.462$). The majority of participants perceived the availability of hydroponic to be 'very easy' (61%; 59% in 2023) or 'easy' (28%; 31% in 2023) (Figure 24A).

Bush Cannabis


Price: Consistent with previous years, the median price per gram of bush cannabis was \$20 (IQR=20-20; n=29; \$20 in 2023; IQR=15-20; n=42; $p=0.281$). The price per ounce of bush cannabis significantly decreased from \$250 (IQR=200-250; n=20) in 2023 to \$180, (IQR=150-240; n=17; $p=0.039$) (Figure 22B).

Perceived Potency: Among those who were able to comment in 2024 (n=153), the perceived potency of non-prescribed cannabis remained stable relative to 2023 ($p=0.820$). The per cent reporting bush to be of 'high' potency was 39% in 2024 (38% in 2023), with an equal per cent perceiving it to be of 'medium' potency (39%; 41% in 2023) (Figure 23B).


Perceived Availability: Among those that were able to comment in 2024 (n=155), the perceived availability of non-prescribed cannabis remained stable relative to 2023 ($p=0.437$). The majority of participants perceived the availability of bush cannabis to be 'very easy' (47%; 49% in 2023) or 'easy' (32%; 29% in 2023) (Figure 24B).

Figure 22: Median price of non-prescribed hydroponic (A) and bush (B) cannabis per ounce and gram, nationally, 2003-2024

(A) Hydroponic cannabis




(B) Bush cannabis




Note. Among those who commented. From 2003 onwards hydroponic and bush cannabis data collected separately. Data from 2022 onwards refers to non-prescribed cannabis only: prior to 2022, we did not distinguish between prescribed and non-prescribed cannabis, and as such it is possible that 2017-2021 figures include some participants who reported on the price of prescribed cannabis (with medicinal cannabis first legalised in Australia in November 2016), although we anticipate these numbers would be very low. The error bars represent the IQR. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 23: Current perceived potency of non-prescribed hydroponic (A) and bush (B) cannabis, nationally, 2004-2024

(A) Hydroponic cannabis




(B) Bush cannabis




Note. Hydroponic and bush cannabis data collected separately from 2004 onwards. Data from 2022 onwards refers to non-prescribed cannabis only: prior to 2022, we did not distinguish between prescribed and non-prescribed cannabis, and as such it is possible that 2017-2021 figures include some participants who are reporting on the potency of prescribed cannabis (with medicinal cannabis first legalised in Australia in November 2016), although we anticipate these numbers would be very low. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 24: Current perceived availability of non-prescribed hydroponic (A) and bush (B) cannabis, nationally, 2004-2024

(A) Hydroponic cannabis



(B) Bush cannabis



Note. Hydroponic and bush cannabis data collected separately from 2004 onwards. Data from 2022 onwards refers to non-prescribed cannabis only: prior to 2022, we did not distinguish between prescribed and non-prescribed cannabis, and as such it is possible that 2017-2021 figures include some participants who are reporting on the availability of prescribed cannabis (with medicinal cannabis first legalised in Australia in November 2016), although we anticipate these numbers would be very low. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

7

Pharmaceutical Opioids

The following section describes recent (past six month) use of pharmaceutical opioids amongst the sample. Terminology throughout this chapter refers to **prescribed use**: use of pharmaceutical opioids obtained by a prescription in the person's name; **non-prescribed use**: use of pharmaceutical opioids obtained from a prescription in someone else's name; and **any use**: use of pharmaceutical opioids obtained through either of the above means. Contact the Drug Trends team (drugtrends@unsw.edu.au) for information on price and perceived availability of non-prescribed pharmaceutical opioids.


Methadone

Any Recent Use (past 6 months): Since peaking at 52% in 2005 and 2008, respectively, a gradual decline in any methadone use is observed. In 2024, one quarter (25%) of the sample reported any recent use, a significant decline from 31% in 2023 ($p=0.009$), representing the lowest per cent observed since monitoring commenced (Figure 25). Historically, methadone use has largely consisted of prescribed use (21% in 2024; 24% in 2023; $p=0.096$), with the per cent reporting non-prescribed methadone use gradually declining to 7% in 2024 (9% in 2023; $p=0.137$), the lowest per cent reported since monitoring commenced (Figure 25). The per cent reporting non-prescribed use remained low and stable across capital city samples in 2024 (Table 10).

Frequency of Use: Frequency of non-prescribed methadone syrup use in the six months preceding interview significantly increased from a median of four days in 2023 (IQR=1-14; $n=69$) to 12 days in 2024 (IQR=3-48; $n=57$; $p=0.041$) (Figure 25).

Recent Injecting Use: Of those who had recently used methadone syrup or tablets and commented ($n=224$), one quarter (25%) reported injecting methadone, stable relative to 2023 (27%; $p=0.528$). Participants who reported injecting methadone did so on a median of 40 days (IQR=12-86), a significant increase from 12 days in 2023 (IQR=3-72; $p=0.048$).

Figure 25: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed methadone, nationally, 2000-2024



Note. Includes methadone syrup and tablets except where otherwise specified. Non-prescribed use not distinguished in 2000-2002. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Secondary Y axis reduced to 30 days to improve visibility of trends. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 10: Past six month non-prescribed use of methadone, by capital city, 2003-2024

%	Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
2003	20	27	13	76	33	18	39	18
2004	29	30	11	75	19	20	35	28
2005	19	34	11	60	27	27	41	22
2006	28	39	11	63	28	32	33	20
2007	24	34	21	66	27	31	33	20
2008	27	35	21	70	17	19	45	27
2009	36	26	20	68	10	11	32	11
2010	27	25	19	58	17	13	27	15
2011	25	25	22	53	15	27	30	16
2012	26	27	21	47	14	31	27	12
2013	29	29	12	51	20	24	13	16
2014	29	27	21	51	9	20	16	17
2015	25	16	17	36	11	14	17	14
2016	21	12	13	40	6	13	14	19
2017	19	13	7	39	6	-	18	19
2018	20	13	11	42	-	9	8	18
2019	22	15	7	29	8	-	13	19
2020	17	7	10	26	9	11	-	20
2021	19	14	5	32	7	6	10	13
2022	18	8	7	16	-	9	-	10
2023	12	10	12	11	-	7	~	7
2024	12	6	5	10	-	7	-	8

Note. Includes methadone syrup and tablets. From 2000-2002, the IDRS did not distinguish between prescribed and non-prescribed methadone use. ~Due to the particularly small samples recruited in Darwin in 2023 (n<50), data are not presented in this table. Statistical significance for 2023 versus 2024 is presented in table; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.


Buprenorphine Tablet

Any Recent Use (past 6 months): Since peaking at 35% in 2005 and 2006, respectively, the per cent reporting recent use of any buprenorphine in tablet form has gradually declined over time. In 2024, 8% of the national sample reported recent use of any buprenorphine tablet, stable relative to 2023 (8%; $p = 0.851$) (Figure 26). Three per cent reported prescribed use (3% in 2023; $p = 0.667$), and 5% reported non-prescribed use (6% in 2023; $p = 0.504$) (Figure 26). Recent non-prescribed use remained low across all capital city samples, with a significant decrease observed in the Hobart sample, from 20% in 2023 to 8% in 2024 ($p = 0.034$) (Table 11).

Frequency of Use: Participants reported use of non-prescribed buprenorphine in tablet form on a median of 10 days in 2024 (IQR=2-90; n=42; 12 days in 2023; IQR=2-48; n=45) (Figure 26).

Recent Injecting Use: Of those who had recently used buprenorphine in tablet form in 2024 and commented (n=68), 59% reported recent injection, stable relative to 2023 (59%). Participants who reported injecting buprenorphine tablet did so on a median of 15 days (IQR=6-90) in the six months preceding interview, also stable from 2023 (6 days; IQR=2-74; $p = 0.196$).

Figure 26: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed buprenorphine tablet, nationally, 2002-2024



Note. Non-prescribed use not distinguished in 2002. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Secondary Y axis reduced to 40 days to improve visibility of trends. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 11: Past six month non-prescribed use of buprenorphine tablet, by capital city, 2003-2024

%	Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
2003	5	-	32	-	10	18	13	7
2004	8	-	35	-	12	23	15	20
2005	8	15	29	-	14	34	20	20
2006	19	34	29	6	14	32	14	30
2007	16	28	26	6	11	19	-	31
2008	7	25	19	-	12	18	18	25
2009	18	23	25	12	9	16	-	31
2010	13	27	21	-	9	18	8	27
2011	12	21	18	6	8	11	8	33
2012	13	20	19	6	9	14	10	22
2013	11	16	9	9	7	10	20	16
2014	22	12	12	11	-	19	12	19
2015	9	11	12	13	6	8	10	17
2016	11	8	4	10	-	9	16	26
2017	13	14	6	9	7	10	-	25
2018	-	9	5	11	-	8	-	12
2019	4	-	-	-	0	-	-	15
2020	5	0	0	11	-	9	0	14
2021	5	-	-	11	-	-	-	20
2022	-	-	4	7	-	-	-	15
2023	5	-	-	20	-	-	~	11
2024	-	-	-	8*	-	6	-	16

Note. In 2002, the IDRS interview did not distinguish between prescribed and non-prescribed use. ~Due to the particularly small samples recruited in Darwin in 2023 (n<50), data are not presented in this table. Statistical significance for 2023 versus 2024 is presented in table; * $p<0.050$; ** $p<0.010$; *** $p<0.001$. Please refer to Table 1 for a guide to table/figure notes.


Buprenorphine-Naloxone

Any Recent Use (past 6 months): After remaining relatively stable from 2009-2015, the per cent reporting any recent buprenorphine-naloxone use has been gradually declining over the past decade. In 2024, 13% of the sample reported recent use of any buprenorphine-naloxone, stable from 2023 (14%; $p=0.327$). Four per cent reported recent prescribed use in 2024, a significant decrease from 7% in 2023 ($p=0.020$), and 9% reported non-prescribed use, stable relative to 2023 (9%; $p=0.865$) (Figure 27). Recent non-prescribed buprenorphine-naloxone use remained low and stable in all capital city samples in 2024 (Table 12).

Frequency of Use: In 2024, participants reported using non-prescribed buprenorphine-naloxone on a median of seven days (IQR=4-30; n=80) in the six months preceding interview, a significant increase from five days in 2023 (IQR=2-12; n=72; $p=0.008$) (Figure 27).

Recent Injecting Use: Of those who had recently used buprenorphine-naloxone in 2024 and commented (n=112), 48% reported injecting as a route of administration, stable from 54% in 2023 ($p=0.429$). Participants reported injecting buprenorphine-naloxone on a median of 12 days (IQR=3-61) in the six months preceding interview (6 days in 2023; IQR=2-28; $p=0.215$).

Figure 27: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed buprenorphine-naloxone, nationally, 2006-2024



Note. From 2006-2011 participants were asked about the use of buprenorphine-naloxone tablet; from 2012-2016 participants were asked about the use of buprenorphine-naloxone tablet and film; from 2017 onwards, participants were asked about the use of buprenorphine-naloxone film only. Median days of non-prescribed use computed among those who reported recent use (maximum 180 days) and is only reported from 2012 onwards to capture film use. Median days rounded to the nearest whole number. Secondary Y axis reduced to 30 days to improve visibility of trends. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 12: Past six month non-prescribed use of buprenorphine-naloxone (any form), by capital city, 2006-2024

%	Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
2006	-	-	5	-	-	9	-	7
2007	-	6	13	-	-	15	-	24
2008	-	10	18	-	-	12	-	16
2009	6	11	14	-	9	28	8	22
2010	-	12	24	-	8	17	15	21
2011	8	12	29	-	-	14	14	11
2012 [#]	9	9	23	11	18	22	8	15
2013	9	11	17	9	9	22	19	22
2014	15	16	15	11	9	18	20	16
2015	11	12	17	13	15	19	22	27
2016	11	7	14	7	6	-	9	23
2017 [^]	14	13	11	14	14	16	10	24
2018	9	16	12	12	-	7	-	18
2019	11	14	10	7	8	16	10	22
2020	-	-	4	23	11	12	-	15
2021	-	9	5	21	10	13	-	11
2022	5	-	7	13	8	9	-	10
2023	8	-	6	18	8	9	~	15
2024	8	-	5	10	10	14	11	13

Note. Data collected from 2006 onwards. # Includes 'tablet' and 'film' forms from 2012-2016. ^ Includes only 'film' form from 2017 onwards. ~Due to the particularly small samples recruited in Darwin in 2023 (n<50), data are not presented in this table. Statistical significance for 2023 versus 2024 is presented in table; *p<0.050; **p<0.010; ***p<0.001. Please refer to Table 1 for a guide to table/figure notes.


Morphine

Any Recent Use (past 6 months): After remaining relatively stable from 2001-2007, the per cent reporting recent morphine use has been declining from 2008 onwards (Figure 28). In 2024, 13% of the national sample had recently used any morphine (13% in 2023; $p=0.824$). Nationally, this per cent mostly comprised of non-prescribed use (10%; 10% in 2023; $p=0.935$). Non-prescribed morphine use remained largely stable across all capital city samples (Table 13). Four per cent of the national sample reported recent prescribed use in 2024 (4% in 2023; $p=0.804$).

Frequency of Use: Since peaking at a median of 26 days of use in 2014, a gradual decline in the frequency of non-prescribed morphine use has been observed. In 2024, participants reported a median of five days of non-prescribed use (IQR=2-36; n=89), the lowest median days of use reported since monitoring commenced (7 days in 2023; IQR=2-24; n=81; $p=0.240$) (Figure 28).

Recent Injecting Use: Of those who had recently used morphine and commented (n=117), four fifths (82%) reported injecting as a route of administration, stable relative to 2023 (81%; $p=0.859$). Those who reported injecting morphine did so on a median of six days (IQR=2-48) in the six months preceding interview, stable from 2023 (12 days; IQR=3-72; $p=0.126$).

Figure 28: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed morphine, nationally, 2001-2024



Note. Non-prescribed use not distinguished in 2001-2005. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Secondary Y axis reduced to 30 days to improve visibility of trends. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 13: Past six month non-prescribed use of morphine, by capital city, 2006-2024

%	Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
2006	31	52	31	58	48	52	70	51
2007	34	53	37	67	41	45	73	57
2008	31	35	40	81	30	31	85	51
2009	28	38	31	81	22	33	61	38
2010	31	36	30	73	24	28	89	38
2011	21	30	33	73	20	33	72	39
2012	21	30	27	64	23	43	69	34
2013	19	23	20	65	22	37	74	38
2014	25	12	24	71	20	27	80	32
2015	19	20	13	47	20	19	69	29
2016	16	12	10	51	18	16	71	33
2017	16	21	7	42	12	18	60	26
2018	17	10	10	47	7	14	54	29
2019	13	11	9	26	10	15	40	28
2020	7	8	8	38	11	18	32	21
2021	9	9	6	40	8	16	36	18
2022	11	10	7	27	10	7	27	19
2023	8	6	5	20	8	11	~	8
2024	9	8	-	26	9	6	14*	11

Note. From 2001-2005, the IDRS did not distinguish between prescribed and non-prescribed morphine ~Due to the particularly small samples recruited in Darwin in 2023 (n<50), data are not presented in this table. Statistical significance for 2023 versus 2024 is presented in table; *p<0.050; **p<0.010; ***p<0.001. Please refer to Table 1 for a guide to table/figure notes.


Oxycodone

Any Recent Use (past 6 months): The percentage of participants reporting recent oxycodone use peaked at 39% in 2012, gradually decreased from 2013 to 2019, and has remained relatively stable ever since (Figure 29). In 2024, 13% of the national sample had recently used any oxycodone, stable relative to 2023 (14%). Five per cent of the sample reported prescribed use (5% in 2023), and one tenth (10%) reported non-prescribed use (10% in 2023). The per cent reporting recent non-prescribed oxycodone use remained largely stable in all capital city samples in 2024 (Table 14).

Frequency of Use: In 2024, participants reported using non-prescribed oxycodone on a median of five days in the six months preceding interview (IQR=2-16; n=87; 3 days in 2023; IQR=2-14; n=81; p=0.446) (Figure 29).

Recent Injecting Use: Of those who had recently used oxycodone and commented (n=119), almost half (47%) reported injecting as a route of administration, stable relative to 2023 (42%; p=0.502). Participants reported injecting non-prescribed oxycodone on a median of four days in the six months preceding interview (IQR=2-12; 3 days in 2023; IQR=2-11; p=0.228).

Figure 29: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed oxycodone, nationally, 2005-2024



Note. From 2005-2015, participants were asked about recent use and frequency of use for any oxycodone; from 2016-2018, recent use and frequency of use for oxycodone was broken down into three types: tamper resistant ('OP'), non-tamper proof (generic) and 'other oxycodone' (median days non-prescribed use missing from 2016-2018). From 2019, recent use for oxycodone was broken down into four types: tamper resistant ('OP'), non-tamper proof (generic), 'other oxycodone' and oxycodone-naloxone, while frequency of use was asked for any oxycodone. From 2023, participants were asked about recent use and frequency of use for any oxycodone. Median days of non-prescribed use computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Secondary Y axis reduced to 14 days to improve visibility of trends. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 14: Past six month non-prescribed use of oxycodone, by capital city, 2005-2024

%	Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
2005	14	14	16	30	11	39	11	16
2006	18	22	24	29	20	42	7	21
2007	26	23	28	36	20	44	11	39
2008	27	27	25	53	15	23	28	26
2009	27	27	25	56	9	29	35	34
2010	33	13	28	60	17	20	22	26
2011	34	23	37	45	23	30	26	34
2012	46	34	26	56	26	48	19	29
2013	40	17	23	61	18	33	23	37
2014	40	16	22	47	21	27	22	38
2015	21	15	19	27	25	18	23	24
2016	23	12	10	28	16	17	18	22
2017	27	9	8	29	13	14	14	18
2018	16	10	10	28	-	15	11	18
2019	21	14	5	22	13	11	12	20
2020	9	8	7	24	11	8	9	15
2021	9	-	7	17	9	15	-	10
2022	11	6	10	12	10	11	-	11
2023	12	10	7	15	6	10	~	11
2024	9	9	5	21	8	11	0**	16

Note. Data on oxycodone use not collected from 2000-2004. ~Due to the particularly small samples recruited in Darwin in 2023 (n<50), data are not presented in this table. Statistical significance for 2023 versus 2024 is presented in table; * $p<0.050$; ** $p<0.010$; *** $p<0.001$. Please refer to Table 1 for a guide to table/figure notes.


Fentanyl

Any Recent Use (past 6 months): The per cent reporting any recent use of fentanyl has remained low and stable since monitoring commenced, with 5% reporting any recent use in 2024 (7% in 2023; $p=0.119$) (Figure 30). Four per cent reported non-prescribed use (6% in 2023; $p=0.132$) and 1% reported prescribed use (2% in 2023; $p=0.571$). Non-prescribed fentanyl use was low in all capital city samples, with a significant decrease observed in the Hobart and Melbourne samples ($n\leq 5$; 11%; $p=0.007$ and $n\leq 5$; 5% in 2023; $p=0.036$, respectively) (Table 15).

Frequency of Use: In 2024, participants reported non-prescribed use on a median of four days (IQR=1-14; $n=38$) in the six months preceding interview, stable relative to 2023 (2 days; IQR=1-12; $n=48$; $p=0.414$) (Figure 30).

Recent Injecting Use: Of those who had recently used fentanyl and commented ($n=47$), significantly fewer participants reported injecting in 2024 (62%) compared to 2023 (82%; $p=0.032$). Participants reported injecting fentanyl on a median of three days (IQR=1-7) in the past six months (2 days in 2023; IQR=1-9; $p=0.876$).

Figure 30: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed fentanyl, nationally, 2013-2024



Note. Data on fentanyl use not collected from 2000-2012; from 2013-2017, the IDRS did not distinguish between prescribed and non-prescribed use. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Secondary Y axis reduced to 10 days to improve visibility of trends. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 15: Past six month non-prescribed use of fentanyl, by capital city, 2018-2024

%	Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
2018	6	6	8	0	-	8	-	16
2019	11	10	7	-	-	9	13	13
2020	8	9	-	-	10	11	-	-
2021	7	10	-	12	6	6	-	-
2022	4	9	-	10	6	-	0	-
2023	7	7	5	11	-	10	~	-
2024	7	14	-*	-**	-	-	-	-

Note. Data on fentanyl use not collected from 2000-2012; from 2013-2017, the IDRS did not distinguish between prescribed and non-prescribed use. ~Due to the particularly small samples recruited in Darwin in 2023 (n<50), data are not presented in this table. Statistical significance for 2023 versus 2024 is presented in table; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Other Opioids

Participants were asked about prescribed and non-prescribed use of other opioids (Table 16). In 2024, almost one tenth (8%) of participants reported any recent use of codeine (10% in 2023; $p=0.053$), with 4% reporting prescribed use (6% in 2023; $p=0.051$), and 4% reporting non-prescribed use (4% in 2023; $p=0.619$). Of those who reported recent use (n=67), few participants (n≤5) reported injecting as a route of administration (n≤5 in 2023).

In 2024, 6% reported any recent use of tramadol (9% in 2023; $p=0.066$), with 3% reporting prescribed use (5% in 2023; $p=0.081$) and 4% reporting non-prescribed use (4% in 2023; $p=0.530$). Of those who reported recent use (n=55), few participants (n≤5) reported injecting as a route of administration (10% in 2023; $p=0.511$).

Two per cent of the sample reported recent use of tapentadol in 2024, a significant increase from 1% in 2023 ($p=0.034$). One per cent of participants reported prescribed use (n≤5 in 2023; $p=0.346$) and non-prescribed use (0% in 2023; $p=0.079$), respectively. No participants reported injecting as a route of administration in 2024 or 2023. One per cent of participants reported any recent use of other opioids in 2024 (2% in 2023; $p=0.073$) (not listed in Table 16).

Table 16: Past six month use of other opioids, nationally, 2019-2024

%	2019 (N=896)	2020 (N=880)	2021 (N=887)	2022 (n=878)	2023 (N=819)	2024 (N=881)
Codeine[^]						
Any use	9	10	10	9	10	8
Non-prescribed use	9	4	5	4	4	4
Any injecting use [#]	5	7	2	-	-	-
Tramadol						
Any use	16	7	8	10	9	6
Non-prescribed use	7	4	5	5	4	4
Any injecting use [#]	9	8	11	12	10	-
Tapentadol						
Any use	2	1	2	1	1	2*
Non-prescribed use	1	-	-	1	0	1
Any injecting use [#]	-	-	0	0	0	0

Note. [^]Includes high and low dose. [#]Of those who reported past six month use. Statistical significance for 2023 versus 2024 is presented in table; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

8

Other Drugs

Participants were asked about their recent (past six month) use of various other drugs, including use of new psychoactive substances, non-prescribed use (i.e., use of a medicine obtained from a prescription in someone else's name) of other pharmaceutical drugs, and use of licit substances (e.g., alcohol, tobacco).

New Psychoactive Substances (NPS)

NPS are often defined as substances which do not fall under international drug control, but which may pose a public health threat. However, there is no universally accepted definition, and in practicality the term has come to include drugs which have previously not been well-established in recreational drug markets.

Recent Use (past 6 months): In 2024, 5% of the sample reported any recent NPS use, stable relative to 2023 (7%; $p=0.087$) (Table 17). 'New' drugs that mimic the effects of cannabis (2%; 3% in 2023; $p=0.257$) and 'new' drugs that mimic the effects of psychedelics (2%; 2% in 2023; $p=0.490$) were the two most commonly used NPS class. Participants' use of 'new' drugs that mimic the effects of cannabis was infrequent (median 4 days; IQR=1-61; $n=16$; median 2 days in 2023; IQR=1-15; $n=22$; $p=0.615$). One per cent reported use of 'new' drugs that mimic the effects of opioids (1% in 2023; $p=0.480$), 'new' drugs that mimic the effects of ecstasy ($n\leq 5$ in 2023; $p=0.229$) and 'new' drugs that mimic the effects of amphetamines/cocaine (2% in 2023; $p=0.086$), respectively (Table 17).

Table 17: Past six month use of new psychoactive substances, nationally, 2013-2024

%	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
	N=887	N=898	N=888	N=877	N=888	N=905	N=902	N=884	N=887	N=870	N=818	N=883
'New' drugs that mimic the effects of opioids	/	/	/	/	-	-	2	1	1	1	1	1
'New' drugs that mimic the effects of ecstasy	/	/	/	/	1 [#]	1	2	-	1	1	-	1
'New' drugs that mimic the effects of amphetamine or cocaine	4	4	3	4	/	2	1	2	1	2	2	1
'New' drugs that mimic the effects of cannabis	9	8	8	8	5	5	6	5	4	2	3	2
'New' drugs that mimic the effects of psychedelic drugs	/	/	/	/	1 [#]	2	1	1	0	1	2	2
'New' drugs that mimic the effects of benzodiazepines	/	/	/	/	/	-	1	-	1	0	-	-
Any of the above	12	11	10	11	8	11	11	8	7	6	7	5

Note. [#]In 2017, participants were asked about use of 'new drugs that mimic the effects of ecstasy or psychedelic drugs', thus the same value appears in both 'new' drugs that mimic the effects of ecstasy and 'new' drugs that mimic the effects of psychedelic drugs; from 2018 onwards, these two NPS classes were separated out. Statistical significance for 2023 versus 2024 is presented in table; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Non-Prescribed Pharmaceutical Drugs

Benzodiazepines

From 2019 to 2023, participants were asked about their use of non-prescribed alprazolam and non-prescribed use of 'other' benzodiazepines (e.g., diazepam), separately. In 2024, these categories were combined, and as such, participants were asked about non-prescribed use of any benzodiazepines.

Recent Use (past 6 months): Recent use of non-prescribed benzodiazepines has fluctuated over time, peaking at 53% in 2011, and declining thereafter. One quarter (25%) of the sample reported recent use of non-prescribed benzodiazepines (e.g., Valium, Diazepam, Xanax, Kalma) in the six months preceding interview, stable relative to 2023 (28%; $p=0.118$) (Figure 31).

Frequency of Use: In 2024, participants reported using non-prescribed benzodiazepines on a median of 10 days (IQR=4-48; $n=219$) in the six months preceding interview.

Recent Injecting Use: In 2024, 4% of participants who had recently used any non-prescribed benzodiazepines reported injecting as a route of administration (3% in 2023; $p=0.795$). Similarly, 5% of participants who had recently used any benzodiazepines (prescribed or non-prescribed) reported injecting as a route of administration (2% in 2023; $p=0.104$).

Forms used: Among those who reported non-prescribed benzodiazepine use and responded in 2024 ($n=214$), the most commonly used brands were Valium (diazepam) (73%), followed by Xanax (alprazolam) (27%), Diazepam (generic) (18%), Serepax (oxazepam) (11%) and Rivotril (clonazepam) (10%).

Pharmaceutical Stimulants

Recent Use (past 6 months): Non-prescribed use of pharmaceutical stimulants (e.g., Ritalin, dexamphetamine, Modafinil, Concerta, Vyvanse) gradually decreased between 2006 and 2017, and has remained relatively stable since (Figure 31). In 2024, one tenth (9%) reported recent use, stable from 2023 (8%; $p=0.489$).

Frequency of Use: Frequency of non-prescribed use remained stable at four days in 2024 (IQR=2-8; $n=78$; 3 days in 2023; IQR=1-10; $n=65$; $p=0.430$).

Recent Injecting Use: One fifth (20%) of those who had recently used non-prescribed pharmaceutical stimulants in 2024 reported injecting as a route of administration (32% in 2023; $p=0.132$) and had done so on a median of five days in the past six months (IQR=1-6; 2 days in 2023; IQR=2-8; $p=0.975$).

Antipsychotics

Recent Use (past 6 months): The per cent of the sample reporting recent use of non-prescribed antipsychotics (asked as 'Seroquel' from 2011-2018) gradually decreased between 2011 and 2020 and has remained stable since. In 2024, 5% reported recent use, stable relative to 2023 (5%; $p=0.908$) (Figure 31).

Frequency of Use: Frequency of non-prescribed use remained stable at five days in 2024 (IQR=2-19; n=44; 5 days in 2023; IQR=2-15; n=39; $p=0.755$).

Recent Injecting Use: No participants reported recently injecting antipsychotics in 2024 ($n \leq 5$ in 2023; $p=0.471$).

Pregabalin

Recent Use (past 6 months): In 2024, 13% of the sample reported non-prescribed pregabalin use in the six months preceding interview: this has remained relatively stable since monitoring commenced (16% in 2023; $p=0.193$) (Figure 31).

Frequency of Use: Non-prescribed use was infrequent, with participants reporting use on a median of five days in the preceding six months (IQR=2-15; n=117), consistent with 2023 (median 7 days; IQR=2-21; n=127; $p=0.188$).

Recent Injecting Use: Of those who had recently used non-prescribed pregabalin (n=118), few participants ($n \leq 5$) reported recent injecting use (5% in 2023; $p=0.771$).


Gabapentin

Recent Use (past 6 months): In 2024, 1% of the sample reported non-prescribed gabapentin use in the six months preceding interview (1% in 2023; $p=0.780$) (Figure 31).

Frequency of Use: Participants reported use on a median of eight days in the preceding six months (IQR=2-19; n=6), stable relative to 2023 (median 5 days; IQR=3-7; n=7; $p=0.886$).

Recent Injecting Use: Of those who had recently used non-prescribed gabapentin (n=6), few participants ($n \leq 5$) reported recent injecting use ($n \leq 5$ in 2023).

Figure 31: Past six month use of non-prescribed pharmaceutical drugs, nationally, 2006-2024



Note. Non-prescribed use is reported. Antipsychotics was asked as ‘Seroquel’ from 2011-2018. Pharmaceutical stimulants were separated into prescribed and non-prescribed from 2006 onwards, and benzodiazepines were separated into prescribed and non-prescribed from 2007 onwards. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Licit and Other Drugs

Alcohol

Recent Use (past 6 months): In 2024, 51% of the sample reported recent use of alcohol, the lowest per cent observed since monitoring commenced and a significant decrease from 57% in 2023 ($p=0.020$) (Figure 32).

Frequency of Use: Participants who reported recent alcohol use in 2024 reported use on a median of 24 days (IQR=6-120; $n=448$), stable relative to 2023 (24 days; IQR=6-90; $n=463$; $p=0.647$), with one fifth (21%) reporting daily use (18% in 2023; $p=0.399$).

Tobacco

In 2024, questions about illicit tobacco were included for the first time. Illicit tobacco was defined as products sold illegally without the necessary taxes added to the price.

Recent Use (past 6 months): Tobacco use has remained high since the IDRS commenced. In 2024, 87% of the sample reported recent use, stable from 2023 (88%; $p=0.663$) (Figure 32). Fifty-three per cent of participants reported recent use of illicit tobacco, with the most common products being branded tobacco packs (72%), followed by unbranded loose tobacco (36%) and branded loose tobacco (14%). Twelve per cent reported using unbranded tobacco packs and 2% reported using other illicit tobacco products.

Frequency of Use: Frequency of use remained high among those reporting recent use at a median of 180 days (i.e., daily; IQR=180-180; $n=768$; 180 days in 2023; IQR=180-180; $n=718$; $p=0.298$), with 88% reporting daily use in 2024 (90% in 2023; $p=0.285$). Participants who had recently used illicit tobacco products also reported use on a median of 180 days (IQR=180-180; $n=399$).

E-cigarettes

From October 2021, Australians were required to have a prescription to legally access nicotine containing e-cigarette products for any purpose. In 2022, participants were asked for the first time about their use of both prescribed and non-prescribed e-cigarettes. Few participants reported recent use of prescribed e-cigarettes in 2022 ($n\leq 5$), 2023 (1%) and 2024 (1%; $p=0.618$). The data presented from 2022 to 2024 refers to non-prescribed e-cigarette use, while data for 2021 and earlier years refers to any e-cigarette use.

Recent Use (past 6 months): One quarter (27%) of the sample reported non-prescribed e-cigarette use in 2024, a significant decrease relative to 2023 (34%; $p=0.005$) (Figure 32).

Frequency of Use: Frequency of non-prescribed use remained stable relative to 2023, with participants reporting a median of 90 days of use (i.e., every second day; IQR=12-180; $n=240$; 90 days in 2023; IQR=12-180; $n=273$; $p=0.878$). Daily use of non-prescribed e-cigarettes was reported by 37% of participants who reported recent use, stable relative to 2023 (38%; $p=0.851$).

Contents and Forms Used: Among those who reported recent non-prescribed use and commented (n=226), the majority (87%) reported using e-cigarettes that contained nicotine (81% in 2023; $p=0.069$) and most reported using disposable devices (88%), followed by re-fillable devices (20%).

Seven per cent reported vaping substances other than nicotine/vape juice. Among those who vaped substances other than nicotine/vape juice and commented (n=58), the most commonly vaped substances were cannabis (64%), followed by methamphetamine crystal (19%) and DMT (16%).

Reason for Use: Forty-two per cent of those who had recently used any (i.e., prescribed or non-prescribed) e-cigarettes in 2024 reported that they had used e-cigarettes as a smoking cessation tool, a significant decrease from 56% in 2023 ($p=0.003$).

Nicotine Pouches

Recent Use (past 6 months): Three per cent of the sample reported recent use of nicotine pouches in 2024 (not asked in 2023) (Figure 32).

Frequency of Use: Participants reported using nicotine pouches on a median of four days (IQR=1-23; n=24) in the six months preceding interview.

Kava

Recent Use (past 6 months): One per cent of the sample reported recent use of Kava, stable relative to 2023 (1%; $p=0.800$) (Figure 32).

Frequency of Use: Among those who had recently consumed Kava and responded (n=9), participants reported a median of two days of use (IQR=1-8), stable relative to 2023 (2 days; IQR=1-2; n=50; $p=0.469$).

Steroids

Recent Use (past 6 months): Reports of recent use of non-prescribed steroids have remained consistently low (between <1% and 3%) since monitoring commenced in 2010. One per cent of the sample reported recent use in 2024 (1% in 2023; $p=0.618$) (Figure 32).

GHB/GBL/1,4-BD

Recent Use (past 6 months): In 2024, 15% of the sample reported recent use of GHB/GBL/1,4-BD, stable relative to 2023 (17%; $p=0.155$) (Figure 32).

Frequency of Use: Participants reported use of GHB/GBL/1,4-BD on a median of five days in the preceding six months (IQR=2-20; n=131), consistent with 2023 (median 4 days; IQR=2-20; n=143; $p=0.414$).

Recent Injecting Use: Of those who reported recent use (n=131), 5% reported injecting as a route of administration (4% in 2023).

Unisom


Unisom SleepGels is a Schedule 3 medicine containing diphenhydramine that is available over-the-counter from a pharmacist for use as an antihistamine or temporary sleep aid. It comes in a gel capsule

formulation intended for oral use. There have been [reports](#) of injecting use in Australia, raising concern of attendant injecting-related injuries.

Recent Use (past 6 months): In 2024, 2% of the national sample reported use of Unisom in the six months preceding interview (3% in 2023; $p=0.876$) (Figure 32).

Recent Injecting Use: Of those who had recently used Unisom ($n=22$), 77% reported injecting as a route of administration (86% in 2023; $p=0.698$).

Figure 32: Past six month use of licit and other drugs, nationally, 2000-2024



Note. Regarding e-cigarette use, on 1 October 2021, legislation came into effect requiring people to obtain a prescription to legally import nicotine vaping products. Data from 2022 onwards refers to non-prescribed e-cigarettes only. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

9

Drug-Related Harms and Other Behaviours


Participants were asked about various drug-related harms and other behaviours, including polysubstance use and bingeing, non-fatal overdose, AUDIT-C, naloxone awareness and uptake, equipment access and injecting behaviours, injection-related injuries and diseases, drug treatment, opioid and methamphetamine dependence, bloodborne virus testing and treatment, sexual health behaviours, mental health and psychological distress, health service access, driving under the influence of drugs, drug checking and crime. It should be noted that the following data refer to participants' understanding of these behaviours (e.g., may not represent medical diagnoses in the case of reporting on health conditions).

Polysubstance Use

In 2024, the majority of the sample (93%) reported using one or more drugs (including alcohol and prescription medications, but excluding tobacco and e-cigarettes) on the day preceding interview. Of those who reported using one or more drugs and commented (n=816), the most commonly used substances were cannabis (53%), stimulants (50%), opioids (50%), alcohol (23%), and benzodiazepines (13%).

Almost two thirds (63%) of the sample reported using two or more drugs (including alcohol and prescription medications, but excluding tobacco and e-cigarettes) on the day preceding interview. Almost one fifth (19%) reported concurrent use of cannabis and stimulants, and 9% reported concurrent use of opioids and cannabis, on the day preceding interview (Figure 33). Seventeen per cent of respondents reported using stimulants alone, 15% reported using opioids alone, and 9% reported using cannabis alone.

Figure 33: Use of opioids, stimulants, benzodiazepines and cannabis on the day preceding interview and most common drug pattern profiles, nationally, 2024




Note. % calculated out of total IDRS 2024 sample. The horizontal bars represent the per cent of participants who reported use of each drug class on the day preceding interview; the vertical columns represent the per cent of participants who used the combination of drug classes represented by the blue circles. Participants who did not report use of any of the four drug classes depicted are not shown in the figure but are counted in the denominator. 'Stimulants' includes methamphetamine, cocaine, ecstasy and pharmaceutical stimulants. 'Opioids' includes heroin, methadone, morphine, oxycodone, buprenorphine, buprenorphine-suboxone, fentanyl, other pharmaceutical opioids (codeine, tapentadol, tramadol, etc). Use of benzodiazepines, opioids and stimulants could be prescribed or non-prescribed use. Y axis reduced to 20% to improve visibility of trends.

Binge Drug Use

Participants were asked whether they had used any drug/s for 48 hours or more continuously without sleep (i.e., binged) in the six months preceding interview. The per cent of the sample who have reported bingeing has remained stable over time. In 2024, three fifths (61%) of the sample had binged on one or more drugs in the preceding six months, stable from 2023 (62%) (Figure 34).

Figure 34: Past six month use of drugs for 48 hours or more continuously without sleep ('binge'), nationally, 2018-2024



Note. Participants were first asked about bingeing in 2018. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to tables and figures.

Overdose Events

Non-Fatal Overdose

There have been some changes in the way questions about overdose have been asked over the years, which may account for some variation in estimates.

From 2019 onwards, participants were asked about their past 12-month experience of overdose where symptoms aligned with the examples provided and effects were outside their normal experience, or they felt professional assistance may have been helpful. We specifically asked about:

- **Opioid overdose** (e.g., reduced level of consciousness, respiratory depression, turning blue, collapsing and being unable to be roused). Participants who reported this experience were asked to identify all opioids involved in such events in the past 12 months;
- **Non-opioid overdose** (e.g., nausea, vomiting, chest pain, tremors, increased body temperature, increased heart rate, seizure, extreme paranoia, extreme anxiety, panic, extreme agitation, hallucinations). Drugs other than opioids were split into the following:
 - **Stimulant overdose:** Stimulant drugs include ecstasy, methamphetamine, cocaine, MDA, methylone, mephedrone, pharmaceutical stimulants and stimulant NPS (e.g., MDPV, Alpha PVP); and
 - **Other drug overdose:** 'Other drugs' include (but are not limited to) alcohol, cannabis, GHB/GBL/1,4-BD, amyl nitrite/alkyl nitrite, benzodiazepines and LSD.

It is important to note that overdose episodes reported across the drug types may not be unique given high rates of polysubstance use amongst the sample.

Each year we compute the total per cent of participants who have experienced any past 12-month overdose event by looking for any endorsement across the drug types queried (see Table 18).

Despite some fluctuation since monitoring commenced in 2000, the per cent reporting **any past 12 month non-fatal overdose** has remained relatively stable. In 2024, one fifth (21%) of the sample reported any past 12-month non-fatal overdose, stable relative to 2023 (18%; $p=0.164$) (Figure 35). Non-fatal overdose in the past 12-months remains stable in most capital city samples in 2024 (Table 18). There was, however, a significant decrease observed in the Adelaide sample (27%; 8% in 2023; $p<0.001$).


Twelve per cent reported a **non-fatal overdose following opioid use** in the past 12 months (12% in 2023; $p=0.877$), whilst 6% reported a **non-fatal overdose following stimulant use** in the past 12 months (5% in 2023; $p=0.211$) (Table 18).

The most commonly cited substance involved in past year non-fatal overdose was heroin (11%; 9% in 2023; $p=0.298$). Participants who had overdosed on an opioid ($n=104$) had done so on a median of two occasions (IQR=1-3) in the last 12 months. Among those who had overdosed on an opioid in the past year and commented ($n=101$), 55% reported being administered naloxone, 45% reported that an

ambulance had attended their most recent overdose, 28% were admitted to an emergency department and 11% reported receiving oxygen. Fifteen per cent reported not receiving any treatment. The main reason for not seeking treatment was because they 'decided it wasn't serious enough' (40%). The most commonly cited other drugs involved in participants' most recent opioid overdose were cannabis (25%), benzodiazepines (including alprazolam; 24%), alcohol (18%) and methamphetamine crystal (15%).

Please contact the Drug Trends team (drugtrends@unsw.edu.au) to request further findings regarding non-fatal overdose in the IDRS sample.

Figure 35: Past 12-month any non-fatal overdose, nationally, 2000-2024



Note. Estimates from 2000-2005 refer to heroin and morphine non-fatal overdose only. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 18: Past 12-month non-fatal overdose by drug type, nationally, 2022-2024, and by capital city, 2024

	National		Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/G C
	N=820	N=884	N=150	N=100	N=150	N=102	N=106	N=103	N=70	N=103
	2023	2024	2024	2024	2024	2024	2024	2024	2024	2024
% Any opioid	N=809 12	N=881 12	N=150 10	N=98 17	N=150 19	N=102 -	N=106 9	N=102 18	N=70 0	N=103 14
% Heroin overdose	N=806 9	N=878 11	N=148 9	N=98 16	N=150 19	N=102 0	N=105 6	N=102 18	N=70 0	N=103 13
% Methadone overdose	N=806 1	N=878 -	N=148 -	N=98 -	N=150 -	N=102 -	N=105 0	N=102 -	N=70 0	N=103 0
% Morphine overdose	N=806 -	N=878 -	N=148 0	N=98 0	N=150 0	N=102 -	N=105 0	N=102 0	N=70 0	N=103 0
% Oxycodone overdose	N=806 -	N=878 -	N=148 0	N=98 -	N=150 0	N=102 0	N=105 0	N=102 0	N=70 0	N=103 0
% Stimulant overdose	N=805 5	N=873 6	N=148 5	N=97 11	N=149 -	N=99 13	N=105 10	N=102 -	N=70 -	N=103 10
% Other overdose	N=805 4	N=873 6	N=148 5	N=97 8	N=149 -	N=99 12	N=105 10	N=102 -	N=70 0	N=103 10
% Any drug overdose	N=811 18	N=881 21	N=150 17	N=98 30	N=150 22	N=102 22	N=106 27	N=102 19	N=70 -	N=103 24

Note. Participants reported on whether they had overdosed following use of the specific substances; other substances may have been involved on the occasion(s) that participants refer to. N is the number who responded (denominator). Statistical significance for 2023 versus 2024 is presented in table for national estimates; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Alcohol Use Disorders Identification Test-Concise (AUDIT-C)

The Alcohol Use Disorders Identification Test ([AUDIT](#)) was designed by the World Health Organization (WHO) as a brief screening scale to identify individuals with problematic alcohol use in the past 12 months. The AUDIT-C is a modified version of the 10 question AUDIT instrument, comprising three questions and is scored on a scale of 0-12.

The mean score on the AUDIT-C for the total sample (including participants who had not consumed alcohol in the past 12 months) was 2.9 (SD 3.9) in 2024, a significant decrease relative to 2023 (3.3; SD 3.8; $p = 0.003$).

AUDIT-C scores of ≥ 4 (men) and ≥ 3 (women) are likely to indicate hazardous drinking, and potentially, alcohol dependence (Table 19). In 2024, one third (36%) of male participants (42% in 2023; $p = 0.042$) had obtained a score of four or more, and one third (35%) of female participants (39% in 2023; $p = 0.362$) had obtained a score of three or more, indicative of hazardous use.

Table 19: AUDIT-C total scores and per cent of participants scoring above recommended levels, nationally, 2010-2024

	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
	Men														
Mean AUDIT-C score (SD)	4.1 (3.9)	4.3 (3.9)	4.1 (3.9)	4.3 (4.0)	4.5 (4.0)	4.1 (3.9)	4.1 (3.9)	4.6 (3.6)	3.5 (3.6)	3.7 (3.8)	6.4 (3.5)	6.8 (3.4)	3.5 (4.0)	3.4 (3.8)	3.0 (3.9)
Score of ≥4 (%)	50	50	48	50	53	49	46	53	41	43	71	81	41	42	36*
	Women														
Mean AUDIT-C score (SD)	3.2 (3.4)	3.6 (3.7)	3.5 (3.5)	3.6 (3.6)	3.9 (3.8)	3.4 (3.8)	3.4 (3.6)	4.0 (3.5)	3.5 (3.7)	2.7 (3.4)	5.3 (3.4)	5.7 (3.5)	3.2 (3.8)	3.0 (3.8)	2.7 (3.8)
Score of ≥3 (%)	45	51	50	49	53	44	47	54	49	36	74	77	44	39	35

Note. Monitoring of AUDIT commenced in 2010. Computed from the entire sample regardless of whether they had consumed alcohol in the past twelve months. Statistical significance for 2023 versus 2024 is presented in table; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Naloxone Program and Distribution

Naloxone is a short-acting opioid antagonist that has been used for over 40 years to reverse the effects of opioids. In 2012, a take-home naloxone program commenced in the ACT (followed by NSW, VIC, and WA) through which naloxone was made available to peers and family members of people who inject drugs for the reversal of opioid overdose. In early 2016, the Australian Therapeutic Goods Administration (TGA) placed ‘naloxone when used for the treatment of opioid overdose’ on a dual listing of Schedule 3 and Schedule 4, meaning naloxone could be purchased OTC at pharmacies without a prescription, and at a reduced cost via prescription. From 1 December 2020 to 30 June 2022, under the take home naloxone pilot program, naloxone was made available free of charge and without a prescription in NSW, SA and WA. Following the evaluation of this pilot, the Australian Government announced that a national take home naloxone program was to be implemented in all Australian states and territories from 1 July 2022. Furthermore, naloxone nasal spray (Nyxoid) is now available in Australia as a PBS-listing, which is expected to increase use of naloxone in the community.

Awareness of Naloxone: From 2013-2024, at least four in five participants reported awareness of naloxone in each year, with 80% reporting awareness in 2024 (80% in 2023) (Figure 36). There was large variation across capital city samples, however, ranging from 96% among Canberra participants to 40% among Darwin participants (Table 20).

Awareness of Take-Home Naloxone: In 2024, three quarters (73%) of participants had heard about take-home naloxone, stable relative to 2023 (73%; $p=0.957$) (Figure 36). In 2024, 2% of the national sample reported having heard of paid access, a significant decrease relative to 2023 (6%; $p < 0.001$), and 72% of participants reported having heard of free access (70% in 2023; $p=0.445$). In 2024, knowledge regarding the take-home naloxone program was highest among the Canberra sample (92%), followed by the Melbourne sample (88%) (Table 20).

Obtained Naloxone: In 2024, 54% of the sample reported having obtained naloxone at least once in their lifetime, stable relative to 2023 (53%; $p=0.662$), with 46% having done so in the past year, also stable compared to 2023 (44%; $p=0.405$) (Figure 37). The majority of participants who had ever obtained naloxone and responded ($n=475$) reported most recently accessing it from a Needle and Syringe Program (NSP) (57%), followed by a pharmacy (11%). The majority (95%) reported that they did not have to pay the last time they obtained naloxone.


Two per cent of the sample reported that they had tried to obtain naloxone in their lifetime but had been unsuccessful (2% in 2023; $p=0.751$), with 2% reporting this had occurred in the past year (1% in 2023; $p=0.670$). An additional 48% of participants reported that they had never tried to obtain naloxone (note: a small per cent of participants reported never trying to obtain naloxone despite having obtained it in their lifetime – this could reflect that they had been given naloxone, but never actively sought it out) (49% in 2023; $p=0.590$). Out of those who ever had trouble obtaining naloxone or had never tried to obtain naloxone ($n=432$), the reasons included: 'didn't consider myself/my peers at risk of overdose' (22%), 'don't use opioids' (21%) and 'didn't know you could access naloxone' (10%).

Of those who had ever obtained naloxone, had used opioids in the past month and responded ($n=474$), 44% reported that they 'always' had naloxone on hand when using opioids, followed by 19% reporting 'often', 15% 'sometimes', 8% 'rarely' and 15% 'never'.

Education on Using Naloxone: In 2024, half (51%) of the sample had been trained in how to administer naloxone in their lifetime, stable relative to 2023 (52%; $p=0.771$), with 29% having done so in the past year, also stable compared to 2023 (32%; $p=0.177$) (Figure 37). Among those who had been trained in naloxone administration in the last year and responded ($n=251$), three fifths (60%) were taught how to administer naloxone at an NSP, followed by a 'health service' (8%), 'other harm reduction service' and drug treatment service' (6%, respectively).


Use of Naloxone to Reverse Overdose: In 2024, one quarter (27%) of the sample reported that they had resuscitated someone using naloxone at least once in their lifetime, stable relative to 2023 (29%; $p=0.441$), with 17% having done so in the past year. In 2024, of those who responded ($n=881$), 5% reported that they had been resuscitated by a peer using naloxone in the past year (5% in 2023; $p=0.750$).

Figure 36: Lifetime awareness of naloxone and naloxone take-home programs, nationally, 2013-2024



Note. [^]Wording of this question changed from 'Have you heard about take home naloxone programs' (after receiving a blurb about what these programs entailed: 2013-2022) to 'Are you aware that naloxone is available for people to take home' in 2023. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 37: Past 12 month education in naloxone administration, and obtained naloxone, nationally, 2020-2024



Note. ^{^^}Wording of this question changed from 'Have you ever been through a naloxone training course? This may include brief advice, brief education or more extensive training' (2020-2022) to 'Have you ever been taught how to use naloxone? This may include brief advice, brief education or more extensive training' (2023 onwards). Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 20: Lifetime awareness of naloxone, and past year access and education in naloxone administration, by capital city, 2024

	Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
	N=150	N=100	N=150	N=102	N=106	N=103	N=70	N=103
% Heard of naloxone	N=149 89	N=99 96	N=150 94	N=102 75	N=106 66	N=102 84	N=70 40	N=103 76
% Heard of take-home naloxone	N=149 85	N=99 92	N=150 88	N=102 68	N=106 40	N=102 81	N=70 39	N=103 70
% Obtained naloxone in past year	N=149 60	N=99 63	N=149 60	N=102 32	N=106 21	N=102 58	N=70 10	N=103 40
% Trained in naloxone administration in past year	N=149 44	N=99 44	N=149 30	N=102 25	N=105 10	N=102 21	N=70 9	N=103 33

Note. N is the number who responded (denominator). Please refer to Table 1 for a guide to table/figure notes.

Equipment Access and Injecting Behaviours

Equipment Access

In 2024, participants reported obtaining a median of 100 new needle and syringes in the past month (IQR=20-200; 100 in 2023; IQR=20-150; $p=0.895$), having a median of 12 needles and syringes 'stored away' (IQR=1-50; 10 in 2023; IQR=1-60; $p=0.669$) and providing a median of 10 needles and syringes to others (IQR=0-45; 8 in 2023; IQR=0-40; $p=0.494$).

Eleven per cent of the sample reported difficulties obtaining new needles and syringes in the past month (9% in 2023; $p=0.180$) (Table 21), and 2% reported difficulties accessing filters (3% in 2023; $p=0.303$). The majority of participants reported that they obtained needles from a Needle and Syringe Program (NSP) (88%; 83% in 2023; $p=0.014$) in the past month, followed by a NSP vending machine (24%; 25% in 2023; $p=0.815$).

Injecting Behaviours

In 2024, participants reported injecting on a median of 25 occasions in the past month (IQR=12-31; 20 occasions in 2023; IQR=10-31; $p=0.380$). In 2024, 5% of the sample reported receptive sharing (5% in 2023; $p=0.746$) and 9% reported distributive sharing (7% in 2023; $p=0.251$) in the past month. The per cent who had shared other injecting equipment (e.g., spoons, tourniquet, water, and filters) in the month preceding interview more than halved between 2000 (51%) and 2011 (25%) and remained relatively stable from 2011-2023 (notwithstanding a sharp decline in 2019). Fifteen per cent reported sharing other equipment in 2024, a significant decrease relative to 2023 (21%; $p=0.002$) and the second lowest per cent reported since monitoring commenced (Table 22 and Figure 38). The per cent of the sample who reported re-using their own needles in the past month has also declined over time, though remained stable in 2024 (35%), relative to 2023 (33%; $p=0.332$) (Table 22 and Figure 38).

One third (34%) of the 2024 sample reported that they had injected someone else after injecting themselves in the past month, stable relative to 2023 (33%; $p=0.605$) and 17% had been injected by someone else after they had injected themselves (18% in 2023; $p=0.514$) (Table 22).


The location of last injection remained stable between 2023 and 2024 ($p=0.459$). Consistent with previous years, most participants (78%) in the national sample reported that they had last injected in a private home (79% in 2023) (Table 22). Twelve per cent of Melbourne participants and 10% of Sydney participants reported last injecting at the Medically Supervised Injecting Room or Centre (Table 22).

Table 21: Injecting equipment access in past month, nationally, 2023-2024 and by capital city, 2024

	National		Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
	N=820	N=884	N=150	N=100	N=150	N=102	N=106	N=103	N=70	N=103
	2023	2024	2024	2024	2024	2024	2024	2024	2024	2024
% Location of needle/syringe access past month	n=812	n=865	n=150	n=97	n=148	n=98	n=106	n=95	n=69	n=102
NSP	83	88*	82	92	80	93	87	84	99	94
NSP vending machine	25	24	53	6	28	20	35	-	25	8
Chemist	17	11***	7	14	5	18	6	19	-	21
Friend/Partner	18	14*	17	19	5	11	37	9	-	13
Dealer	7	4*	5	-	-	-	13	-	-	-
Hospital	2	2	8	0	-	-	0	0	0	-
Outreach/peer worker	5	2**	-	-	9	0	0	0	-	0
Medically supervised injecting Centre/Room	6	7	21	0	20	0	0	0	0	0
Other	2	2	-	9	-	-	-	-	0	0
%Difficulties accessing filters^ in the past month	3	2	-	-	-	-	-	-	-	-
% Difficulties accessing needles/syringes in past month	9	11	11	6	13	15	18	12	-	6
% Equipment used past month	n=818	n=881	n=150	n=99	n=149	n=102	n=105	n=103	n=70	n=103
Spoons/mixing containers	70	64**	93	89	83	30	30	73	16	61
Tourniquet	52	52	69	59	51	28	44	58	41	51
Swabs	89	85*	94	84	89	70	81	88	96	76
Water	89	88	95	92	76	80	93	93	97	85
Any filters	65	64	85	84	74	50	36	75	33	56

Note. ^Filters included wheel filters, Sterifilt basic filters, sterifilt plus filters and commercial cotton filters (e.g., Stericups). Statistical significance for 2023 versus 2024 is presented in figure for national estimates; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 38: Borrowing and lending of needles and sharing of injecting equipment in the past month, nationally, 2000-2024



Note. Borrowed (receptive): used a needle after someone else. Lent (distributive): somebody else used a needle after them. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 22: Injecting behaviours in the past month, and location of last injection use, nationally, 2023-2024, and by capital city, 2024

	National		Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
	N=820	N=884	N=150	N=100	N=150	N=102	N=106	N=103	N=70	N=103
	2023	2024	2024	2024	2024	2024	2024	2024	2024	2024
% Injecting behaviours past month										
Borrowed a needle	N=810 5	N=880 5	N=150 5	N=99 -	N=149 4	N=101 6	N=106 5	N=102 8	N=70 -	N=103 8
Lent a needle	N=808 7	N=870 9	N=148 12	N=95 -	N=148 7	N=100 9	N=105 8	N=101 15	N=70 -	N=103 8
Shared any injecting equipment ^	N=814 21	N=882 15**	N=150 17	N=100 14	N=150 20	N=101 9	N=106 19	N=102 16	N=70 -	N=103 15
Reused own needle	N=810 33	N=875 35	N=149 34	N=98 44	N=149 38	N=100 25	N=105 39	N=101 44	N=70 19	N=103 33
Injected partner/friend after self~	N=811 33	N=877 34	N=150 -	N=99 -	N=149 -	N=100 -	N=106 0	N=101 0	N=70 0	N=102 -
Somebody else injected them after injecting themselves~	N=810 18	N=887 17	N=150 13	N=98 11	N=149 16	N=101 19	N=105 23	N=101 16	N=70 14	N=103 22
% Location of last injecting use	N=812	N=877	N=150	N=99	N=149	N=100	N=106	N=101	N=70	N=102
Private home	79	78	73	90	62	83	79	74	93	80
Car	4	3	0	-	-	-	-	9	-	-
Street/car park/beach	8	8	9	-	15	6	10	10	-	7
Public toilet	5	6	7	-	5	-	6	7	-	9
Medically supervised injecting Centre/Room	4	4	10	0	12	0	0	0	0	0
Prison	/	0	0	0	0	0	0	0	0	0
Stairwell	/	-	0	0	-	-	-	0	0	0
Other	1	1	-	-	-	-	0	0	0	-

Note. Borrowed (receptive): used a needle after someone else. Lent (distributive): somebody else used a needle after them. ^ Includes spoons, water, tourniquets and filters; excludes needles/syringes. ~ With a new or used needle. N is the number who responded (denominator). Statistical significance for 2023 versus 2024 is presented in table for national estimates; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Self-Reported Injection-Related Injuries and Diseases

In 2024, 29% of the sample reported having an injection-related health issue in the month preceding interview, stable relative to 2023 (26%; $p=0.215$) (Table 23). The most common injection-related health issue reported by participants was any infection/abscess (13%; 10% in 2023; $p=0.071$) and any nerve damage (12%; 10% in 2023; $p=0.196$).

Table 23: Injection-related issues in the past month, nationally, 2023-2024, and by capital city, 2024

	National		Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
	N=817	N=877	N=148	N=100	N=150	N=100	N=106	N=102	N=68	N=103
	2023	2024	2024	2024	2024	2024	2024	2024	2024	2024
% Artery Injection	4	6	-	6	4	-	9	11	0	12
% Any nerve damage	10	12	11	14	8	13	22	11	-	17
% Any thrombosis	6	6	-	8	6	7	10	8	0	7
Blood clot	6	5	-	8	4	-	10	8	0	6
Deep vein thrombosis	-	1	0	0	-	-	-	-	0	-
% Any infection/abscess	10	13	16	14	6	14	21	10	-	17
Skin abscess	9	11	14	11	5	11	18	8	-	15
Other serious infection (e.g., sepsis, osteomyelitis)	1	3	-	-	-	-	-	-	0	-
Endocarditis	-	1	-	-	0	0	-	-	-	-
% Dirty hit	6	7	7	-	-	7	10	10	-	11
% Any injection related problem	26	29	29	31	20	30	40	31	-	38

Note. Statistical significance for 2023 versus 2024 is presented in table for national estimates; * $p<0.050$; ** $p<0.010$; *** $p<0.001$. Please refer to Table 1 for a guide to table/figure notes.

Drug Treatment

In 2024, almost two fifths (37%) of the sample reported that they were in any drug treatment for their substance use, stable from 39% in 2023 ($p=0.424$), with the most common treatment being methadone (19%; 21% in 2023; $p=0.337$), followed by buprenorphine depot injection (7%; 7% in 2023; $p=0.921$) (Table 24). Among those who reported methadone or buprenorphine treatment and commented ($n=216$), 69% reported receiving takeaway doses of methadone/buprenorphine (77% in 2023; $p=0.088$).


Amongst those who were currently receiving drug treatment and commented (n=321) in 2024, 76% of participants reported being satisfied with their current treatment (78% in 2023; $p=0.620$), with a further one tenth (12%) reporting being dissatisfied (11% in 2023; $p=0.790$) (Figure 39). One tenth (10%) of participants reported having tried to access treatment in the past six months but were unable to, a significant decrease from 14% in 2023 ($p=0.012$). The most commonly cited drug the last time treatment was required for comprised methamphetamine (44%; 43% in 2023; $p=0.885$), followed by heroin (40%; 42% in 2023; $p=0.777$). The most common service that participants had tried to access, but been unable to, were rehabilitation/therapeutic community (38%; 41% in 2023; $p=0.773$) and detoxification (30%; 14% in 2023; $p=0.012$), with the most common reasons being ‘too hard to get into treatment (e.g., no places available, long waiting list)’ (55%; 53% in 2023; $p=0.885$), ‘lack of support’ (26%; 23% in 2023; $p=0.625$) and ‘other’ (18%; 33% in 2023; $p=0.020$).

Table 24: Any current drug treatment, nationally, 2022-2024, and by capital city, 2024

	National		Syd	Can	Mel	Hob	Ade	Per	Dar	Bri/GC
	N=820	N=884	N=150	N=100	N=150	N=102	N=106	N=103	N=70	N=103
	2023	2024	2024	2024	2024	2024	2024	2024	2024	2024
% Any current drug treatment	39	37	46	45	53	24	14	43	11	40
Methadone	21	19	27	23	37	8	8	18	-	13
Buprenorphine	1	2	-	-	-	-	-	0	-	6
Buprenorphine-naloxone	5	3	-	-	-	-	-	10	-	-
Buprenorphine depot injection	7	7	11	8	12	-	-	9	0	6
Drug counselling	7	6	9	11	-	-	-	-	0	16
Other	2	3	-	9	-	7	-	-	0	7

Note. Statistical significance for 2023 versus 2024 is presented in table for national estimates; * $p<0.050$; ** $p<0.010$; *** $p<0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 39: Treatment satisfaction amongst those who reported current treatment, nationally, 2019-2024



Note. 'Too early to say' excluded from analysis. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Opioid and Methamphetamine Dependence

From 2017, participants were asked questions from the Severity of Dependence Scale (SDS) adapted to investigate opioid and methamphetamine dependence. The SDS is a five-item tool designed to screen for potential dependence on a variety of drugs. The SDS focuses on the psychological aspects of dependence, including impaired control of drug use, preoccupation with, and anxiety about use. A total score was created by summing responses to each of the five questions. Possible scores range from 0 to 15.

To assess methamphetamine dependence in the past six months, a [cut-off value of four](#) was used, as this has been found to be a good balance between sensitivity and specificity for identifying dependent methamphetamine use. No validated cut-off for opioid dependence exists; however, researchers typically use a [cut-off value of five](#) as an indicator of likely dependence.

Of those who had recently used an opioid and commented (n=530), the median SDS score was six (IQR=2-9), with almost three fifths (59%) scoring five or above, indicating possible dependence (57% in 2023; $p=0.618$) (Table 25). Fifteen per cent of participants obtained a score of zero on the opioid SDS (17% in 2023; $p=0.360$), indicating no symptoms of opioid dependence.

Of those who had recently used methamphetamine and commented (n=696), the median SDS score was three (IQR=1-7), with 49% scoring four or above, indicating possible dependence (47% in 2023; $p=0.543$) (Table 25). One fifth (22%) of participants obtained a score of zero on the methamphetamine SDS, indicative of no symptoms of methamphetamine dependence (25% in 2023; $p=0.220$).

Table 25: Total opioid and methamphetamine SDS scores and per cent of participants scoring above cut-off scores indicative of dependence, among those who reported past six month use, nationally, 2017-2024

	2017	2018	2019	2020	2021	2022	2023	2024
Opioid	N=659	N=659	N=618	/	N=553	N=530	N=527	N=530
Median total score (IQR)	7 (3-10)	5 (1-9)	6 (3-10)	/	6 (2-9)	5 (2-9)	5 (2-9)	6 (2-9)
% score = 0	12	25	12	/	14	16	17	15
% score ≥ 5	67	57	63	/	57	58	57	59
Methamphetamine	N=609	N=680	N=673	/	N=700	N=666	N=638	N=696
Median total score (IQR)	3 (0-6)	1 (0-6)	3 (0-6)	/	3 (0-7)	3 (0-6)	3 (1-7)	3 (1-7)
% score = 0	31	44	30	/	28	26	25	22
% score ≥ 4	45	36	42	/	47	47	47	49

Note. Severity of Dependence scores calculated out of those who used opioids/methamphetamine recently (past 6 months). A cut-off score of ≥5 and ≥4 is used to indicate screening positive for potential opioid and methamphetamine dependence, respectively. Imputation used for missing scale scores. Statistical significance for 2023 versus 2024 is presented in table; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Bloodborne Virus Testing and Treatment

In 2024, 53% of participants reported that they had received a hepatitis C virus (HCV) antibody test in the past year, stable relative to 2023 (52%; $p=0.734$). Forty-four per cent had received a PCR or RNA test in the past year, stable compared to 2023 (44% in 2023; $p=0.876$) and 4% reported having a current HCV infection (7% in 2023; $p=0.062$) (Table 26). Six per cent of the sample reported that they had received HCV treatment in the past year, a significant decrease from 8% in 2023 ($p=0.039$), of which the majority (77%; $n=36$) reported that their treatment had been successful (75% in 2023; $p=0.821$). Eighty-five per cent of these participants reported having been re-tested with a PCR/RNA test to determine whether they had acquired a new HCV infection (re-infection) after successful treatment (77% in 2023; $p=0.398$).

Amongst those who had undergone an HCV RNA test in the last year and commented ($n=353$), almost two fifths (39%) reported it took 1-5 days to receive a result (whether positive or negative), following the administration of the last HCV RNA test, followed by one third (33%) reporting more than five days.

Four fifths (81%) of the total sample reported having had a test for human immunodeficiency virus (HIV) in their lifetime (30% within the past six months; 33% in 2023; $p=0.186$), of which 3% reported a positive diagnosis (3% in 2023) (Table 26).

Table 26: HCV and HIV testing and treatment, nationally, 2018-2024

	2018	2019	2020	2021	2022	2023	2024
%	N=905	N=902	N=884	N=888	N=879	N=820	N=884
Past year Hepatitis C test							
Past year hepatitis C antibody test	N=861 60	N=876 54	N=861 31	N=868 44	N=846 43	N=785 52	N=847 53
Past year hepatitis C PCR or RNA test	N=794 45	N=817 44	N=831 36	N=839 40	N=803 37	N=751 44	N=833 44
Current hepatitis C status							
Currently have hepatitis C [^]	N=807 20	N=823 15	N=836 11	N=826 9	N=805 7	N=737 7	N=808 4
Past year treatment for hepatitis C							
Received treatment in past year	N=852 18	N=794 15	N=854 9	N=862 12	N=835 10	N=749 8	N=830 6*
Most recent treatment was successful (among those who had received treatment in past year)	N=99 94	N=79 97	N=80 72	N=100 69	N=85 69	N=63 75	N=47 77
Re-tested with a PCR or RNA test to determine re-infection (among those who underwent successful treatment)	/	/	/	/	/	N=43 77	N=34 85
HIV test							
HIV test in past 6 months	/	/	/	N=864 31	N=823 23	N=789 33	N=835 30
HIV test more than 6 months ago	/	/	/	53	55	51	50
HIV status							
Lifetime HIV positive diagnosis	/	/	/	N=722 4	N=633 3	N=669 3	N=672 3

Note. [^]This includes people who had not been tested for HCV. N is the number who responded (denominator). Timeframes for HCV and HIV differ; i.e., HCV questions focus on current and past year; HIV questions focus on lifetime and past six months. Statistical significance for 2023 versus 2024 is presented in table; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Sexual Health Behaviours

In 2024, 44% of the sample reported some form of sexual activity in the past four weeks, stable relative to 2023 (47%; $p = 0.198$) (Table 27). Given the sensitive nature of these questions, participants were given the option of self-completing this section of the interview (if the interview was undertaken face-to-face).

Amongst those who reported engaging in sexual activity in the past four weeks and commented ($n = 366$), participants reported a median of one partner (IQR=1-2; median of 1 partner in 2023; IQR=1-2; $p = 0.187$). One tenth (10%) reported engaging in sexual activity in the past four weeks in exchange for money, drugs, or other goods and services (Table 27) (data not collected in 2023).

Of those who commented ($n = 831$), almost one-quarter (23%) reported having a sexual health check-up in the six months prior to interview (24% in 2023; $p = 0.594$), whilst 61% had done so in their lifetime (64% in 2023; $p = 0.176$). Two per cent of the sample reported that they had received a positive diagnosis for a sexually transmitted infection (STI) in the past six months in 2024, stable relative to

2023 (2%; $p=0.851$) and 18% had received a positive diagnosis in their lifetime (17% in 2023; $p=0.900$) (Table 27). The most common STI reported amongst participants who commented ($n=15$) was chlamydia (67%), followed by gonorrhoea (40%), with few participants ($n\leq 5$) reporting other STIs.

Information about HIV testing provided in Table 26.

Table 27: Sexual health behaviours, nationally, 2022-2024

	2022	2023	2024
Of those who responded#:	N=809	N=788	N=837
% Any sexual activity in the past four weeks	48	47	44
Of those who reported any sexual activity in the past four weeks and responded#:	/	/	n=362
% Engaged in sexual activity in exchange for money, drugs or other goods or services	/	/	10
Of those who responded#:	N=813	n=786	n=831
% Had a sexual health check in the last six months	17	24	23
% Had a sexual health check in their lifetime	60	64	61
Of those who responded#:	n=813	n=784	n=830
% Diagnosed with a sexually transmitted infection in the last six months	1	2	2
% Diagnosed with a sexually transmitted infection in their lifetime	15	17	18


Note. # Due to the sensitive nature of these items, there is missing data for some participants who chose not to respond. Statistical significance for 2023 versus 2024 is presented in table; * $p<0.050$; ** $p<0.010$; *** $p<0.001$. Please refer to Table 1 for a guide to table/figure notes.

Mental Health and Psychological Distress (K10)

Mental Health

In 2024, half (53%) of the sample self-reported that they had experienced a mental health problem in the preceding six months, stable relative to 2023 (53%), and the highest per cent reported for the second year running since monitoring commenced. Amongst those who had experienced a mental health problem, the most commonly reported problems were depression (63%; 59% in 2023; $p=0.399$) and anxiety (59%; 53% in 2023; $p=0.202$). Fewer participants reported post-traumatic stress disorder (PTSD) (29%), schizophrenia (19%) and bipolar disorder (15%). One quarter of the total sample (27%; 51% of those who reported a mental health problem) had seen a mental health professional during the past six months, stable from 2023 (27%; 51% of those who reported a mental health problem) (Figure 40). Two thirds (66%) of those who reported having seen a health professional about a mental health problem had been prescribed medication for their mental health problem in the preceding six months (73% in 2023; $p=0.132$).

Figure 40: Self-reported mental health problems and treatment seeking in the past six months, nationally, 2004-2024



Note. The combination of the per cent who report treatment seeking and no treatment is the per cent who reported experiencing a mental health problem in the past six months. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.


Psychological Distress (K10)

The [Kessler Psychological Distress Scale 10 \(K10\)](#) was administered to obtain a measure of psychological distress in the past four weeks. It is a 10-item standardised measure that has been found to have good psychometric properties and to identify clinical levels of psychological distress as measured by the Diagnostic and Statistical Manual of Mental Disorders/the Structured Clinical Interview for DSM disorders.

The minimum score is 10 (indicating no distress) and the maximum is 50 (indicating very high psychological distress). Scores can be coded into four categories to describe degrees of distress: scores from 10–15 are considered to indicate ‘low’ psychological distress; scores between 16–21 indicate ‘moderate’ psychological distress; scores between 22–29 indicate ‘high’ psychological distress; and scores between 30–50 indicate ‘very high’ psychological distress. Among the general population, scores of 30 or more have been demonstrated to indicate a high likelihood of having a mental health problem, and possibly requiring clinical assistance. The K10 scores remained stable between 2023 and 2024 ($p = 0.052$), with 34% having a score of 30 or more (29% in 2023) (Figure 41).

The [National Health Survey 2022-23](#) provides Australian population data for adult (≥ 18 years) K10 scores. IDRS participants in 2024 reported greater levels of ‘high’ and ‘very high’ distress compared to the general population (Figure 41).

Figure 41: K10 psychological distress scores, nationally, 2007-2024 and among the general population 2022-23




Note. Data from the National Health Survey are a national estimate from 2022-23 for adults 18 or older. Imputation used for missing scale scores (IDRS only). Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Health Service Access

Eighty-four per cent of participants reported accessing any health service for alcohol and/or drug (AOD) support in the six months preceding interview in 2024, a significant decrease relative to 2023 (89%; $p = 0.010$) (Figure 42). The most common services accessed by participants for AOD support in 2024 were a NSP (74%; 76% in 2023; $p = 0.370$), a GP (34%; 37% in 2023; $p = 0.362$) and a pharmacy (24%; not asked in 2023) (Table 28).

Nearly all participants (96%) reported accessing any health service for any reason in the six months preceding interview in 2024, stable relative to 2023 (96%; $p = 0.614$) (Figure 42). The most common services accessed by participants for any reason in 2024 were a NSP (82%; 80% in 2023; $p = 0.219$), a GP (64%; 66% in 2023; $p = 0.502$) and the pharmacy (46%; not asked in 2023) (Table 28).

Figure 42: Health service access for alcohol and other drug reasons, and for any reason in the past six months, nationally, 2018-2024



Note. Questions regarding health service access for any reason were first asked in 2018. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Table 28: Types of health services accessed for alcohol and other drug reasons and for any reason in the past six months, nationally, 2022-2024

	AOD support			Any reason		
	2022	2023	2024	2022	2023	2024
% accessing health services	N=877 82	N=820 89	N=884 84*	N=879 91	N=820 96	N=884 96
GP	34	37	34	61	66	64
Emergency department	10	13	12	22	28	25
Hospital admission (inpatient)	8	9	9	17	20	20
Medical tent (e.g., at a festival)	0	-	-	1	1	-
Drug and Alcohol counsellor	17	16	13	17	17	14
Hospital as an outpatient	3	5	5	9	12	10
Specialist doctor (not including a psychiatrist)	5	3	2	10	10	8
Dentist	5	4	4	16	13	13
Ambulance attendance	6	7	7	11	14	14
Pharmacy	/	/	24	/	/	46
Other health professional (e.g., physiotherapist)	2	2	2	8	11	8*
Psychiatrist	6	5	5	11	11	9
Psychologist	6	4	6	11	9	10
NSP	69	76	74	71	80	82
Peer based harm reduction service	10	10	7*	11	11	7**
Other harm reduction service	6	7	8	6	7	9

Note. Statistical significance for 2023 versus 2024 is presented in table; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.


Driving

One third (33%) of participants had driven a car, motorcycle or other vehicle in the last six months in 2024, a significant decrease relative to 2023 (38%; $p=0.047$). Of those who had driven within the last six months and commented ($n=279$), 9% ($n=24$) reported driving while over the perceived legal limit of alcohol, stable relative to 2023 (8%; $p=0.876$). Among those who had driven within the last six months and commented ($n=282$), 77% ($n=217$) reported driving within three hours of consuming an illicit or non-prescribed drug, also stable relative to 2023 (70%; $p=0.064$) (Figure 43).

Of those who had driven within three hours of consuming an illicit or non-prescribed drug in the last six months and responded ($n=216$), participants most commonly reported using methamphetamine crystal (59%) prior to driving, followed by heroin (40%) and cannabis (37%).

Of those who had driven in the six months prior to interview and commented ($n=283$), 19% ($n=54$) reported that they had been tested for drug driving by the police roadside drug testing service (20% in 2023; $p=0.912$), and 30% ($n=85$) reported that they had been breath tested for alcohol by the police roadside testing service (30% in 2023) (Figure 43).

Figure 43: Self-reported testing, and driving over the (perceived) legal limit for alcohol or within three hours following illicit drug use, among those who had driven in the last six months, nationally, 2007-2024




Note. Computed of those who had driven a vehicle in the past six months. Questions about driving behaviour were first asked about in 2007. Statistical significance for 2023 versus 2024 is presented in figure; * $p<0.050$; ** $p<0.010$; *** $p<0.001$. Please refer to Table 1 for a guide to table/figure notes.

Drug Checking

Drug checking is a common strategy used to test the contents and purity of illicit drugs. At the time interviewing commenced in 2024, the only government-sanctioned drug checking services that had operated in Australia were at the Groovin the Moo festival in Canberra, ACT (2018, 2019), at CanTEST, a pilot fixed-site drug checking service in Canberra which has been operational since 17 July 2022, and at CheQpoint. Queensland’s first fixed-site drug checking service in Brisbane, which opened on April 20, 2024. CheQpoint, opened a second service on the Gold Coast in July 2024, shortly after IDRS recruitment had finished.

In 2024, 15% of participants reported that they or someone else had ever tested the contents and/or purity of their illicit drugs in Australia, stable relative to 2023 (15%), with 11% having done so in the past year (9% in 2023; $p=0.096$) (Figure 44). Of those who reported that they or someone else had tested their illicit drugs in the past year in 2024 and responded ($n=89$), 44% reported using testing strips (e.g., BTNX fentanyl strips or other immunoassay testing strips), followed by 35% reporting using colorimetric or reagent test kits. Of those who had used testing strips in the past year ($n=39$), no participants reported receiving a positive detection for fentanyl.

Figure 44: Lifetime and past year engagement in drug checking, nationally, 2019-2024



Note. Statistical significance for 2023 versus 2024 is presented in figure; * $p<0.050$; ** $p<0.010$; *** $p<0.001$. Please refer to Table 1 for a guide to table/figure notes.

Experience of Crime and Engagement with the Criminal Justice System

Past month self-reported criminal activity declined to the lowest per cent observed since monitoring commenced in 2013 (36%), and, despite some fluctuations, has remained largely stable since. However, in 2024, 'any' past month crime significantly increased relative to 2023 (44%; 38% in 2023; $p=0.019$).


Property crime (28%) and selling drugs for cash profit (24%) remained the most common self-reported crimes in 2024, stable relative to 2023 (24%; $p=0.071$ and 21%; $p=0.262$, respectively). Fewer participants reported past month violent crime (4%; 4% in 2023) or fraud (3%; 3% in 2023; $p=0.656$) (Figure 45). Being the victim of a crime involving violence (e.g., assault) in the month preceding interview remained stable in 2024, relative to 2023 (14%; 13% in 2023; $p=0.660$) (Figure 46).

Three fifths of the sample (59%) reported a lifetime prison history in 2024, stable relative to 2023 (60%; $p=0.547$) (Figure 47).

Almost one third (32%) of participants reported a drug-related encounter with police which did not result in charge or arrest, stable relative to 2023 (36%; $p=0.155$) (Figure 47). This predominantly comprised being stopped and searched (65%; 69% in 2023; $p=0.470$), followed by stopped and questioned (51%; 64% in 2023; $p=0.003$). Thirty per cent were stopped and issued a court attendance notice (27% in 2023; $p=0.403$), and almost one quarter (23%) were stopped and issued a caution (24% in 2023; $p=0.841$).


In 2024, almost one quarter of participants (24%) reported past year arrest, stable from 2023 (24%; $p=0.685$) (Figure 47). Of those who had been arrested and commented ($n=194$), the main reasons for arrest in 2024 were use/possession of drugs (29%), followed by property crime (28%).

Figure 45: Self-reported criminal activity in the past month, nationally, 2000-2024




Note. 'Any crime' comprises the per cent who report any property crime, drug dealing, fraud and/or violent crime in the past month. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 46: Victim of crime involving violence in the past month, nationally, 2019-2024



Note. Questions regarding being the victim of a crime involving violence were first asked in 2019. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Figure 47: Lifetime incarceration, and past 12 month arrest and drug-related encounters with police that did not result in arrest, nationally, 2003-2024



Note. Statistical significance for 2023 versus 2024 is presented in figure; * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$. Please refer to Table 1 for a guide to table/figure notes.

Modes of Purchasing Illicit or Non-Prescribed Drugs

In interviewing and reporting, 'online sources' were defined as either surface or darknet marketplaces.

Purchasing Approaches

In 2024, the most popular means of arranging the purchase of illicit or non-prescribed drugs in the 12 months preceding interview was face-to-face (85%), a significant increase relative to 79% in 2023 ($p=0.004$) (Table 29). This was followed by phone call (54%; 56% in 2023; $p=0.263$) and text messaging (35%; 34% in 2023; $p=0.570$). Thirteen per cent reported using social networking or messaging applications (e.g., Facebook, Wickr, WhatsApp, Snapchat, Grindr, Tinder) (11% in 2023; $p=0.178$). It is important to re-iterate that this refers to people *arranging the purchase* of illicit or non-prescribed drugs. This captures participants who messaged friends or known dealers on Facebook Messenger or WhatsApp, for example, to organise the purchase of illicit or non-prescribed drugs, which may have then been picked up in person.

Table 29: Purchasing approaches in the past 12 months, nationally, 2023-2024

	2023	2024
% Purchasing approaches in the last 12 months[^]	N=809	N=873
Face-to-face	79	85**
Surface web	1	1
Darknet market	1	2
Social networking or messaging applications [`]	11	13
Text messaging	34	35
Phone call	56	54
Grew/made my own	/	2
Other	/	-

Note. [^] participants could endorse multiple responses. [#]This refers to people *arranging the purchase* of illicit or non-prescribed drugs. [`] This captures participants who messaged friends or known dealers on Facebook Messenger or WhatsApp, for example, to organise the purchase of illicit or non-prescribed drugs, which may have then been picked up in person. Statistical significance for 2023 versus 2024 presented in table; * $p<0.050$; ** $p<0.010$; *** $p<0.001$. Please refer to Table 1 for a guide to table/figure notes.